curriculum vitae sewon kang, m.d. current ...december, 2009 curriculum vitae sewon kang, m.d....

December, 2009

CURRICULUM VITAE

Sewon Kang, M.D.

CURRENT POSITION Noxell Professor of Dermatology

Chair of the Department of Dermatology

Dermatologist-in-Chief, Johns Hopkins Hospital

Johns Hopkins Medicine

ADDRESS Office: Department of Dermatology

Cancer Research Building II, Suite 209


1550 Orleans Street

Baltimore, Maryland 21231

Tel: (410) 955-8662

FAX: (410) 955-8645

EDUCATION

Graduate: University of Michigan Medical School

Ann Arbor, Michigan

Degree: M.D., June 1987

University of Michigan School of Public Health

Ann Arbor, Michigan

Health Degree: M.P.H. in Epidemiology, August 1982

Undergraduate: Williams College

Williamstown, Massachusetts

Degree: B.A. in Chemistry, June 1980

High School: Glenbrook North High School

Northbrook, Illinois

September 1975 - June 1976

Sewon Kang, M.D.

POSTGRADUATE TRAINING AND EDUCATION

Longwood Chief Resident (Brigham & Women‟s, Beth Israel,

Boston Children‟s, Dana Farber Hospitals) Department of

Dermatology, Harvard Medical School, Boston, Massachusetts

1991

Residency, Department of Dermatology, Harvard Medical School

Massachusetts General Hospital, Boston, Massachusetts

1988 - 1992

Research Fellowship, Department of Dermatology, Harvard Medical School


1989 - 1990

Internship, Department of Internal Medicine, University of Rochester

Strong Memorial Hospital, Rochester, New York

1987 - 1988

ACADEMIC APPOINTMENT

Noxell Professor & Chair, Department of Dermatology


Arthur C. Curtis Professor of Dermatologic Translational Research

University of Michigan Medical School

Professor (with tenure), Department of Dermatology

University of Michigan, Medical School

2008 - present

2008

2004 - 2008

Associate Professor (with tenure), Department of Dermatology


1998 - 2004

Assistant Professor, Department of Dermatology


1992 - 1998

HONORS AND AWARDS

Instructional Development Fund Award, Center for Research on Learning

and Teaching, University of Michigan

2006

Society for Investigative Dermatology, Galderma Acne Research Award 2006

University of Michigan Medical School TAMS Award 2005, 2007

University of Michigan Medical Student Award for Teaching Excellence 1998, 2004

Finalist, Pre-Clinical Kaiser Permanente Award for Excellence in Teaching 2003, 2004, 2006

& 2007

University of Michigan Medical School Achievement in Clinical Research

Award

2001

Alpha Omega Alpha Student Research Fellowship Mentor Stipend 2001

University of Michigan Medical Student Teacher of the Month Award 2001

University of Michigan Venture Investment Fund Award 2000 - 2002

Lotus Award from the University of Michigan United Asian-American

Medical Student Association

1999

Outstanding Paper, Michigan Dermatologic Society 1996

Outstanding Paper, Michigan Dermatologic Society 1995

University of Michigan Faculty Travel Award 1995

Dermatology Foundation Clinical Career Development Award in Vitamin

D3 and 9-cis Retinoic Acid interaction in normal and psoriatic skin

1994 - 1997

University of Michigan Minority Faculty Development Fund 1993

Beiersdorf Travel Award in Dermatology 1990

M.D. degree with distinction 1987

University of Michigan Medical School Dean's Award for Research 1987

Sewon Kang, M.D.

University of Michigan President's Student Recognition Award 1987

Academic All-American 1987

American Dermatological Association Student Research Fellowship 1986

National Psoriasis Foundation Summer Research Fellowship 1984

HANA Scholar 1986 - 1987

Crusade Scholar 1982 - 1986

B.A. degree awarded with cum laude 1980

Haystack Scholar, Williams College 1977 - 1980

GRANTS

Selected Previous Grant Support

National Institutes of Health & National Center for Research Resources

(UL1RR024986 / KL2RR024987 / TL1RR024988)

“University of Michigan Clinical and Translational Science Award (UM CTSA)”

PI: Dan Clauw, MD

Program Director for Predoctoral Training Grant (TL1): Sewon Kang, MD

2007-2012 Total cost: $54,619,564

National Institutes of Health (1 T32 RR023257-01)

“University of Michigan multidisciplinary predoctoral clinical researchers in training

program (Roadmap T32)”

PI: Sewon Kang, MD

2005-2010 Total cost: $3,279,427

National Institutes of Health (R01 AG25186)

“Collagenase degradation of extracellular matrix in aging”

PI: Gary J Fisher, PhD

Co-Investigator: Sewon Kang, MD

2006-2011 Total cost: $1,710,000

Galderma

“A Comparative Study of Adapalene Gel, 0.3% versus Tretinoin 0.05% Emollient

Cream, for the Treatment of Photodamage”

PI: Sewon Kang, MD

2008-2010 Total cost: $179,688

Abbott

“A phase 3, multicenter study of the efficacy and safety of long-term Adalimumab

treatment in subjects with moderate to severe chronic plaque psoriasis”

PI: Sewon Kang, MD

2005-2008 Total cost: $279,816

Amgen

"Characterization of changes in skin-homing and potentially self-reactive circulating T-

cells in psoriasis patients while taking etanercept"

PI: Sewon Kang, MD

2008-2010 Total Cost: $81,800.

Sewon Kang, M.D.

National Institutes of Health (5R01 AR48077-05)

“UV-induced collagen reduction in treating skin of scleroderma”

PI: Sewon Kang, MD

2001-2007 Total cost: $1,887,500

National Institutes of Health (1R01 AG19364-01A1)

“TGF- Signaling in photoaged and chronically aged human skin”

PI: Gary J Fisher, PhD


2002-2007 Total cost: $1,560,000

National Institutes of Health (1 K24 AR02159-01)

“Clinical translational research in dermatology and mentoring clinical investigators”

PI: Sewon Kang, MD

2000-2006 Total cost: $615,705

National Cancer Institute/Searle/Pharmacia

“A phase II/III randomized, double-blind, placebo-controlled clinical trial of Celecoxib in

subjects with actinic keratoses”

PI: Sewon Kang, MD

2001-2005 Total cost: $242,750

Johnson & Johnson

“Molecular mechanisms of skin repair”

PI: John J. Voorhees, MD

Co-Investigator & Director of Clinical Research: Sewon Kang, MD

1992-2005 Total cost: $33,000,000

National Institutes of Health (SBIR 1R43-AI30876)

“Topical delivery of liposomally-encapsulated interferon”

PI: Norman Weiner, Ph.D.


1994-1996 Total cost: $362,944

Dermatology Foundation (Clinical Career Development Award)

“Vitamin D3 and 9-cis retinoic acid interaction in normal and psoriatic skin”

PI: Sewon Kang, MD

1994-1997 Total cost: $120,000

National Institutes of Health (1RO1-AR4396201)

“Novel treatments for HIV-1 related Psoriasis”

PI: Brian J. Nickoloff, MD, PhD


1995-1998 Total cost: $556,160

Amgen

“A multicenter, open-label, prospective study to evaluate the effectiveness and safety of

Etanercept in the treatment of subjects with psoriasis”

PI: Sewon Kang, MD

2004-2008 Total cost: $200,000

Sewon Kang, M.D.

Immunex

“Double-blind, randomized, placebo-controlled phase II study of Enbrel (etanercept) in

the treatment of psoriasis”

PI: Sewon Kang, MD

2000-2001 Total cost: $56,056

IDEC

“A phase II open-label, multiple-dose, dose escalating study to evaluate the safety and

clinical activity of IDEC-131 in patients with moderate to severe plaque psoriasis”

PI: Sewon Kang, MD

2001-2001 Total cost: $91,600

University of Michigan Health System (Venture Investment Fund Award)

“UVA1 phototherapy for scleroderma”

PI: Sewon Kang, MD

2000-2002 Total cost: $252,396

Johnson & Johnson

“A two-year, double-blind, vehicle-controlled, randomized, multicenter study of Renova

0.05% in the treatment of photodamaged facial skin (Fitzpatrick skin types I, II, III)”

PI: Sewon Kang, MD

1999-2003 Total cost: $133,585

Pfizer

“A randomized, double-blind, double-dummy, placebo-controlled, multicenter study

assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of

moderate to severe age-related skin changes in postmenopausal women”

PI: Sewon Kang, MD

2000-2003 Total cost: $116,695

3M

“Vehicle-controlled, double-blind study to assess the safety and efficacy of Imiquimod

5% cream for the treatment of superficial basal cell carcinoma”

PI: Sewon Kang, MD

2001-2003 Total cost: $76,923

Novartis

“A 12-week, randomized, double-blind, placebo-controlled, multicenter, parallel-group,

dose-finding study to determine the dose-response, safety and tolerability of three doses

(10, 20, 30 mg bid) of SDZ ASM 981 tablets in subjects with chronic plaque-type

psoriasis”

PI: Sewon Kang, MD

2001-2002 Total cost: $45,549

Boehringer Ingelheim

“Phase II, randomized, double-blind, placebo controlled, multicenter, four week trial of

BIRB 796 BS 5, 10, 20 and 30 mg oral tablets versus placebo administered BID in

patients with moderate to severe plaque-type psoriasis”

PI: Sewon Kang, MD

Sewon Kang, M.D.

2001-2003 Total cost: $184,169

Fujisawa

“Tacrolimus pharmacokinetics in adult atopic dermatitis patients after topical

administration of Protopic (Tacrolimus) ointment 0.03% and 0.1%”

PI: Sewon Kang, MD

2001-2003 Total cost: $115,800

Allergan

“A multi-center, double-blind, randomized, placebo-controlled study of the saftey and

efficacy of 12 weeks treatment with Tazarotene 4.5 mg capsules once daily followed by a

12-week post-treatment follow-up period in patients with moderate to very severe plaque

psoriasis”

PI: Sewon Kang, MD

2002-2003 Total cost: $44,125

Allergan

“An evaluation of the safety and efficacy of Tazorac 0.1% cream (QD) and Renova

0.05% cream (QD) in the treatment of subjects with photodamaged facial skin”

PI: Sewon Kang, MD

2002-2003 Total cost: $105,644

Immunex

“Multicenter dose ranging study of the safety and efficacy of Enbrel in psoriasis”

PI: Sewon Kang, MD

2002-2003 Total cost: $125,200

CellGate

“A double-blind, placebo controlled, randomized, parallel group, dose and schedule

comparison of CGC2001 ointment in the treatment of patients with plaque psoriasis”

PI: Sewon Kang, MD

2002-2003 Total cost: $37,800

ICN Pharmaceuticals

“Nonablative laser therapy for acne vulgaris”

PI: Sewon Kang, MD

2002-2003 Total cost: $81,893

Centocor

“A phase 2, multicenter, randomized, double-blind, placebo-controlled trial evaluating

the efficacy and safety of Infliximab (Remicade) induction therapy in patients with

plaque-type psoriasis”

PI: Sewon Kang, MD

2002-2004 Total cost: $84,250

Connetics

“A phase III, multicenter, randomized, double-blind, active- and vehicle-controlled study

of the safety and efficacy of velac gel for the treatment of acne vulgaris”

PI: Sewon Kang, MD

2002-2004 Total cost: $131,250

Sewon Kang, M.D.

Genmab

“A double-blind, placebo controlled, randomized, parallel group clinical trial of anti-CD4

receptor human monoclonal antibody (huMax-CD4) in patients with moderate to severe

chronic plaque psoriasis vulgaris”

PI: Sewon Kang, MD

2003-2004 Total cost: $35,813

Quatrx

“A multi-center, randomized, double-blind, vehicle-controlled, dose-finding, bilateral

plaque comparison study of the safety and efficacy of three concentrations of Qrx-101

ointment in the treatment of mild to moderate plaque psoriasis”

PI: Sewon Kang, MD

2003-2004 Total cost: $36,665

Abbott

“A phase II multicenter study of the safety and efficacy of adalimumab (D2E7) in

subjects with moderate to severe chronic plaque psoriasis”

PI: Sewon Kang, MD

2003-2004 Total cost: $125,490

Galderma

“A multicenter, randomized, double-blind, parallel group study to evaluate the safety and

efficacy of a fixed combination of Adapalene 0.1% and Benzoyl Peroxide 2.5%

(Adapalene and Benzoyl Peroxide topical gel) gel compared to its monads and topical gel

vehicle in subjects with acne vulgaris”

PI: Sewon Kang, MD

2004-2004 Total cost: $56,500

Centocor

“A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating

the efficacy and safety of infliximab induction therapy followed by multiple regimens of

maintenance infliximab therapy in subjects with plaque-type psoriasis”

PI: Sewon Kang, MD

2003-2005 Total cost: $191,000

3M

“Phase II, multiple-dose study to assess safety and efficacy of 0.03%, 0.1%, and 0.3%

concentrations of topical R-850 applied 1, 2, and 3 times a week for 4 weeks in subjects

with actinic keratosis”

PI: Sewon Kang, MD

2004-2005 Total cost: $68,546

SCIENTIFIC ACTIVITIES

Director, Cutaneous Translational Research Program (CTReP)

Department of Dermatology, Johns Hopkins School of Medicine

Baltimore, Maryland

2008 - present

Sewon Kang, M.D.

Director, Clinical Research Unit, Department of Dermatology

University of Michigan Medical Center, Ann Arbor, Michigan

1993 – 2008

Research Fellow, Department of Dermatology, Harvard Medical School


1989 - 1990

Student Research Fellow, Department of Dermatology

University of Michigan Medical School, Ann Arbor, Michigan

1983 - 1987

Student Summer Research Fellow, The Salk Institute for Biologic Research

Tumor Virology Laboratory, La Jolla, California

1978 - 1980

TEACHING ACTIVITIES & APPOINTMENTS

Courses

Teaching Assistant, Departments of Biology and Chemistry, Williams

College

1977-1980

Teaching Assistant, Department of Chemistry, University of Michigan

Creation of a Master‟s Degree Curriculum

1981

Master‟s Degree in Clinical Research, University of Michigan 2006

Mentoring of Clinical/Translational Research Fellows

University of Michigan Undergraduates and Graduates

Jackie Neal Angelica Susi Wendy Schumacher

David Shen Amy Kim Jennifer Rittenberry

Darlene Kassab Lauren Gold George Kallingal

Stacy Erndt Londisa Halili Claire Friedman

Noah Smith Pamela Sharaf Jazmin Munoz

University of Michigan Medical Students

Beata Ryzik Andy Suh Ladan Shahabi

Padma Nallamothu Reza Kafi Heh Shin Kwak

Le Yu Raza Zaidi Semyon Zarkhin

Nada Elbuluk Conroy Chow Robert Egbers

Johns Hopkins Medical Students

Ian Rosenthal, Ph.D. Ashley Antony

Other Medical School Students

Joyce Lee (U Penn) Kathryn Boyse (Ohio State U)

Seung-Bok Lee (Seoul National University)

University of Michigan Dermatology Residents/Fellows

Neil Peters, MD Mary Lu, MD Lone Anderson, MD, Ph.D

Lectures

Lecture; Pharmacology Core Curriculum, MS2, Johns Hopkins University

School of Medicine

2008 - present

Lecturer, Dermatology Core Curriculum, M2 Series, University of

Michigan Medical School

1993-2008

Lecture Series (1 hour weekly) for M4s on Dermatology Clinical Elective,


1993-2008

Sewon Kang, M.D.

Renee Hamlet, MD Kent Krach, MD Jeffery Orringer, MD

Greg Bezanis, MD Valerie Hanft, MD Jennifer Burger, MD

Michael Gifford, MD Ana Petro, MD Beata Ryzik, MD

Sandra Paek, MD Yolanda Rosi, MD Trisha Daley, MD

Luis Garza, MD, PhD Lisa Maier, MD Abena Ofori, MD

Frank Wang, MD Nicole Neuschler, MD Evans Bailey, MD, PhD

Betsy Simon, MD Anna Chien, MD Missy Mesfin, MD

Mark Naftanel, MD Kelly Cha, MD, PhD

Foreign Dermatology Fellows

Kwang Hyun Cho, MD, PhD Jong Yuk Lee, MD PhD Kwang Joong Kim, MD, PhD

Byung Bok Lee, MD, PhD Hyun Chul Choi, MD Jeeho Choi, MD, PhD

Joo Heun Lee, MD, PhD Sonyun Cho, MD, PhD Susan Bauer, MD

Tomas Dam, MD Jin Ho Chung, MD, PhD Moon Kyun Cho, PhD

Hye Jin Choi, MD Thy Thy Do, MD Wonju Lee, MD, PhD

Woo Jin Yun, MD Boncheol Goo, MD Chong Won Choi, MD

Seong Guen Chi, MD

Departmental Seminars

Update on Retinoids, yearly1 hour presentation 1992-2008

Update on Photoaging, yearly 1 hour presentation 1992-2008

Update on Immunopharmacology of Psoriasis, yearly 1 hour presentation 1992-2008

Training Grant Membership

Primary Preceptor, “Training Grant in Cell and Molecular Dermatology”,

National Institutes of Health Training Grant (T32-AR017979-26)

1997-2008

Primary Preceptor in Dermatology, “The University of Michigan Training

Program in Clinical Research”, National Institutes of Health Training

Grant (K30-HL004108-05)

1999-2008

Course Director

Director, Dermatology Core Curriculum, M2 Series, University of

Michigan Medical School

1995-2008

Student Rotations (clinical)

Lecturer for Medical Students in Dermatology Clerkship, Harvard Medical

School

1991

Examination Committee

In-Training Examination Contributor, American Board of Dermatology 1997

Teaching Conferences

“The Best of UH Inpatient Consult Service”, monthly 1 hour presentation

to dermatology residents and clinical faculty

1993-2008

Attending Physician

University of Michigan Health System, Taubman Center, Department of

Dermatology

1992-2008

Clinical Clerkship Coordinator

Sewon Kang, M.D.

Director, Dermatology Clinical Elective, University of Michigan Medical

School

1993-2008

Grand Rounds Presentation

Discussant/Presenter, monthy 2 hour program, Department of Dermatology 1992-2008

In-patient consulting

University of Michigan Health System 1993-2008

American Board of Dermatology

In-training examination contributor 1997


Director, Dermatology Clinical Elective 1993 - 2008

Director, Dermatology Core Curriculum, M II Series 1995 - 2008

Lecturer, Dermatology Core Curriculum, M II Series 1993 - 2008

Harvard Medical School

Lecturer for Medical Students in Dermatology Clerkship 1991

University of Michigan Literature, Science & Art

Teaching Assistant, Organic Chemistry 1981

Williams College

Teaching Assistant, Departments of Biology and Chemistry 1977 - 1980

PROFESSIONAL EXPERIENCE

Biostatistician, Dermatopharmacology Unit

Department of Dermatology, University of Michigan Medical School

1982 - 1983

User-Friendly Computer Software Programmer

Office of Employee Health, University of Michigan Medical Center

1984 - 1985

MEMBERSHIPS IN PROFESSIONAL SOCIETY

American Dermatological Association

Korean Society for Psoriasis Research, Honorary Member

Korean-American University Professors Association

American Society for Clinical Pharmacology and Therapeutics

National Psoriasis Foundation

Dermatology Foundation

Inflammation Research Association

Skin Pharmacology Society

Michigan Dermatological Society

Korean Dermatologic Association of America

since 2004

since 1998

since 1996

since 1996

since 1996

since 1994

since 1993

since 1993

since 1993

since 1992

Sewon Kang, M.D.

American Academy of Dermatology

Society for Investigative Dermatology

American Federation for Medical Research

Harvard House Officer‟s Club

since 1992

since 1992

since 1989

since 1988

NATIONAL AND INTERNATIONAL COMMITTEES AND RESPONSIBILITIES

Society for Investigative Dermatology

Member, Executive Committee

Member, Committee on Finance

Board of Directors

International Task Force

Member, Committee on Education

Member, Committee on Albert M. Kligman Fellowships

Dermatology Foundation

Board of Trustees

Chair, Medical and Scientific Committee

Chair (Michigan), Leaders Society Campaign

Nominating Committee

Chair, Nominating Committee

Member, Medical and Scientific Committee

Vice Chair (Michigan), Leaders Society Campaign,

The Photomedicine Society

President-Elect

Board of Directors

American Acne & Rosacea Society

Founding Director

Chair, Scientific Committee

Board of Directors

Korean Dermatological Association

Member, Bidding Committee for the 2011 World Congress of

Dermatology

Skin of Color Society

A Founding Member of the Board of Directors

American Academy of Dermatology

Member, Development and Industry Liaison Committee

Member, Guidelines/Outcomes Task Force on Atopic Dermatitis

Member, Committee on Research

United States Pharmacopeia (USP) Drug Information

Expert Committee Member (Dermatology)

Korean Dermatologic Association of America

President

American Dermatological Association

2008 – present

2006 – present

2005 – present

2005 – 2007

2003 – 2008

1997 – 2000

2005 – present

2005

2004 – 2006

2004 – 2007

2006 – 2007

2003 – 2005

2000 – 2003

2006 – present

2003 – present

2005 – 2008

2005 – present

2009 – present

2005 – 2007

2002 – 2007

2007 – 2011

2001 – 2003

2008 – present

2000 – 2004

1999 – present

2009 – present

Member, Audit committee

JOURNAL REVIEWER

Translational Research

American Journal of Pathology

Journal of the European Academy of Dermatology

since 2007

since 2006

since 2006

Sewon Kang, M.D.

Journal of Immunology

The FASEB Journal

Journal of Cutaneous Medicine & Surgery

New England Journal of Medicine

Journal of Photochemical and Photobiological Sciences

Experimental Dermatology

Pediatric Dermatology

The Medical Letter on Drugs and Therapeutics

since 2005

since 2004

since 2004

since 2002

since 2002

since 2002

since 2001

since 2001

Photochemistry and Photobiology

Photodermatology, Photoimmunology & Photomedicine

Journal of Dermatological Treatment

Skin Pharmacology

Dermatology (Basel, Switzerland)

British Journal of Dermatology

Journal of Investigative Dermatology

Journal of the American Academy of Dermatology

Archives of Dermatology

since 2000

since 2000

since 1999

since 1998

since 1998

since 1998

since 1997

since 1992

since 1989

EDITORIAL RESPONSIBILITIES

Member, Editorial Board, Journal of the American Academy of 1997 - present

Dermatology

Member, Editorial Board, Clinical Dermatology (Seoul) 1997 – present

Member, Editorial Board, Photodermatology, Photoimmunology & 2009 – present

Photomedicine

GRANT REVIEWER

National Institutes of Health,

a. National Institute of Arthritis and Musculoskeletal and Skin Diseases

1. Special Emphasis Panel for MCRC applications

2. Biomarkers for Rheumatic and Skin Diseases

3. Special Emphasis Panel for K23 Career Development Award

4. Special Emphasis Panel for Dermatomyositis Clinical Trials

5. Chairperson for Special Emphasis Panel for K24 Midcareer

Investigator Award

6. Special Emphasis Panel for Loan Repayment Program

7. Hyperaccelerated Awards/mechanisms in Immunomodulation

Trials

8. R03, Special Emphasis Panel

b. National Center for Complementary and Alternative medicine

2001 – present

Dermatology Foundation 2003 – 2005

The University of Michigan Medical School Biomedical Research

Application- Basic Science Research Partnership

1997

BC (British Columbia) Health Research Foundation 1992

CERTIFICATION AND LICENSURE

Diplomate, American Board of Dermatology 1992

Sewon Kang, M.D.

(recertified until: 2013)

Diplomate, National Board of Medical Examiners 1988

ADMINISTRATIVE POSITIONS

Johns Hopkins Department of Dermatology

Noxell Professor and Chairman 2008 – present


Committee on the Promotion of Academic Clinicians 2009 – present

Agenda Committee of the Advisory Board of the Medical Faculty 2009 – present

University of Michigan Department of Dermatology

Member, Promotions Committee 2001 – 2008

Director, Clinical Research Unit 1993 – 2008

Clinical Research Director, University of Michigan/Johnson & Johnson

Research Alliance (1990 – 2002)

1993 – 2002

Member, Resident Selection Committee 1993 – 2008

Member, Five-Year Departmental Review Committee 1996

University of Michigan Medical School & Hospitals

CTSA Education Program Executive Committee

CTSA Clinical Trial Planning Grants Review Committee

2008 - 2008

2007

Training and Education Workgroup, University of Michigan

NIH CTSA grant

2005 - 2006

Advisory Council Member, University of Michigan NIH

K12/K30 programs

2005 - 2008

Member, Medical Student Clinical Research Task Force 2005 - 2008

Ad Hoc Member, Committee on Sentinel/Adverse Event 2002 - 2003

Member, Committee on Medical Student Research 1984 - 1987; 1997 - 2008

Faculty Career Advisor 1993 - 2008

Member, Diversity and Career Development Committee 1997 - 1999

Search Committee for Director of Dermatopathology

Member, Academic Review Board

1997 - 1998

1992 - 1993

Director, The XVII Midwest Student Medical Research Forum 1985 - 1986

Director, Medical Student Research Forum 1984 - 1987

Member, Student Council 1986 - 1987

Harvard Medical School Department of Dermatology

Member, Resident Selection Committee 1991 - 1992

Member, ABC Committee 1988 - 1992

ISSUED PATENTS

1999 Compositions for assessing 1,25(OH)2D3 activity in skin and for enhancing the

Sewon Kang, M.D.

therapeutic use of 1,25(OH)2D3. US Patent # 5,998,393.

2000 Methods for inhibiting photoaging of skin. US Patent # 6,130,254.

2001 Methods and compositions for preventing and treating chronological aging in human

skin. U.S. Patent # 6,630,516.

2002 Use of natural EGFR inhibitors to prevent side-effects due to retinoid therapy, soaps,

and other stimuli that activate the epidermal growth factor-receptor. U.S. Patent #

6,638,543

2002 Methods for inhibiting photoaging of skin (a modification of US Patent # 6,130,254).

US Patent # 6,365,630.

2005 Methods and compositions for preventing and treating chronological aging in human

skin. (a modification of U.S. Patent # 6,630,516). US Patent # 6,919,072.

2006 Methods and compositions for treating rosacea. US Patent # 7,078,048.

2006 UVA (# 360-400) and UVB (300-325) specific sunscreens. US Patent # 7,147,863.

2007 Compositions and methods for use against acne-induced inflammation and dermal

matrix-degrading enzymes. US Patent 7,268,148

BIBLIOGRAPHY

PUBLICATIONS IN SCIENTIFIC JOURNALS

1. Vanderveen EE, Ellis CN, Kang S, Case P, Headington JT, Voorhees JJ, Swanson A:

Topical minoxidil for hair growth. J Am Acad Dermatol 1984;11:416-421

2. Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN: Oral ibuprofen and

tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984;11:1076-1081

3. Ellis CN, Kang S, Grekin RC, LoBuglio AF, Voorhees JJ: Etretinate therapy for

psoriasis reduces antibody-dependent cell-mediated cytotoxicity of polymorphonuclear

leukocytes. Arch Dermatol 1985;121:877-880

4. Ellis CN, Kang S, Grekin RC, Voorhees JJ, Silva J: Etretinate therapy reduces PMNL

chemotaxis-enhancing properties of psoriatic serum. J Am Acad Dermatol 1985;13:437-

443

5. Kang S, Ellis CN, Grekin RC, Hamilton TA, Voorhees JJ, LoBuglio AF: Etretinate

therapy and immune activities. Arch Dermatol 1986;122:629-630

6. Ellis CN, Fallon JD, Kang S, Vanderveen EE, Voorhees JJ: Topical application of

nonsteroidal anti-inflammatory drugs prevents vehicle-induced improvement of psoriasis.

J Am Acad Dermatol 1986;14:39-43

Sewon Kang, M.D.

7. Wong RC, Gilbert M, Woo TY, Kang S, Peterson C, Ellis CN: Photosensitivity and

isotretinoin therapy. J Am Acad Dermatol 1986;14:1095-1096

8. Ellis CN, Kang S, Vinik AI, Grekin RC, Cunningham WJ, Voorhees JJ: Glucose and

insulin responses are improved in psoriasis patients during therapy with etretinate, a

vitamin A derivative. Arch Dermatol 1987;123:471-475

9. Berman R, Kang S, Imber M, Dover JS: Nevus spilus. J Am Acad Dermatol

1989;21:163-164

10. Kang S, Dover JS: Successful therapy of pyoderma gangrenosum with intravenous

vancomycin and mezlocillin. Br J Dermatol 1990;123:389-393

11. Kang S, Gonzalez E: Photoallergic contact dermatitis. J Am Acad Dermatol

1990;23:546-547

12. Markowitz JA, Cosimi LA, Carey RW, Kang S, Padyk C, Sober AJ, Cosimi AB:

Prognosis following initial recurrence of cutaneous melanoma. Arch Surg

1991;126:703-708

13. Kang S, Barnhill RL, Graeme-Cook F, Randolph G, Nadol TB, Sober AJ: Primary

malignant melanoma of the external auditory canal: a case report with presentation as an

aural polyp. Am J Otol, 1992;13:194-196

14. Kang S (consultant dermatologist): Case Records of the Massachusetts General Hospital.

A 56-year-old man with Waldenstrom's macroglobulinemia and cutaneous and oral

vesicles. Case of the Month. N Engl J Med, 1992;326:1276-1284

15. Kang S, Barnhill RL, Mihm Jr MC, Sober AJ: Multiple primary cutaneous melanomas.

Cancer 1992;70:1911-1916

16. Kenet RO, Kang S, Kenet BJ, Fitzpatrick TB, Sober AJ, Barnhill RL: Clinical diagnosis

of pigmented lesions using digital epiluminescence microscopy: grading protocol and

atlas. Arch Dermatol 1993;129:157-174

17. Kang S, Barnhill RL, Mihm Jr MC, Sober AJ: Histologic regression in malignant

melanoma: an interobserver concordance study. J Cutan Pathol 1993;20:126-129

18. Kang S, Fitzpatrick TB: Debilitating verruca vulgaris in a HIV infected patient:

dramatic improvement with hyperthermia therapy. Arch Dermatol 1994;130:294-296

19. Kang S, Barnhill RL, Mihm Jr MC, Fitzpatrick TB, Sober AJ: Melanoma risk in

individuals with clinically atypical nevi. Arch Dermatol 1994;130:999-1001 (Selected

for reprinting in international edition and AMA Special Journal Abstracts, JAMA

1995;274:284C)

20. Duraiswamy N, Tse Y, Hammerberg C, Kang S, Cooper KD: Distinction of class II

MHC+ langerhans cell-like interstitial dendritic antigen-presenting cells in murine dermis

from dermal macrophages. J Invest Dermatol 1994;103:678-683

Sewon Kang, M.D.

21. Barnhill RL, Aguiar M, Cohen C, Kang S, Kennedy J, Schmidt B, Sober AJ, Solomon

AR. Congenital melanocytic nevi and DNA content: an analysis by flow and image

cytometry. Cancer 1994;74:2935-2943

22. Griffiths CEM, Tranfaglia MG, Kang S: Prolonged occlusion in the treatment of

psoriasis: A clinical and immunohistologic study. J Am Acad Dermatol 1995;32:618-

622

23. Fisher GJ, Reddy AP, Datta SC, Kang S, Yi JY, Chambon P, Voorhees JJ: All-trans

retinoic acid induces cellular retinol-binding protein in human skin in-vivo. J Invest

Dermatol 1995;105:80-86

24. Griffiths CEM, Kang S, Ellis CN, Kim KJ, Finkel LJ, Ortiz-Ferrer L, White GM,

Hamilton TA, Voorhees JJ: Two concentrations of topical tretinoin (retinoic acid) cause

similar improvement of photoaging but different degrees of irritation: a double-blind,

vehicle-controlled comparison of tretinoin 0.1% and 0.025% creams. Arch Dermatol

1995;131:1037-1044

25. Kang S, Duell EA, Fisher GJ, Datta SC, Wang ZQ, Reddy AP, Tavakkol A, Yi JY,

Griffiths CEM, Elder JT, Voorhees JJ: Application of retinol to human skin in-vivo

induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of

retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol

1995;105:549-556 ( Selected for In This Issue )

26. Fader DJ, Kang S: Bedsore of unknown primary site. Arch Dermatol 1995;131:1115-

1116

27. Busam KJ, Berwick M, Blessing K, Fandrey K, Kang S, Karaoli T, Fine J, Cochran AJ,

White WL, Rivers J, Elder DE, Wen DRP, Heyman BH, Barnhill RL: Tumor vascularity

is not a prognostic factor for malignant melanoma of the skin. Am J Pathol

1995;147:1049-1056

28. Fisher GJ, Datta S, Talwar HS, Wang ZQ, Varani J, Kang S, Voorhees JJ: Molecular

basis of sun-induced premature skin aging and retinoid antagonism. Nature

1996;379:335-339 (All authors contributed equally to this work)

29. Stutz JA, Ellis CN, Kang S: Failure of topical polymyxin B to improve mild plaque

psoriasis. Arch Dermatol 1996;132:231

30. Duell EA, Kang S, Voorhees JJ: Retinoic acid isomers applied to human skin in-vivo

each induce a 4-hydroxylase which inactivates only trans retinoic acid. J Invest

Dermatol 1996;106:316-320

31. Kang S, Kim KJ, Griffiths CEM, Wong TY, Talwar HS, Fisher GJ, Gordon D, Hamilton

TA, Ellis CN, Voorhees JJ: Topical tretinoin (retinoic acid) improves early stretch

marks. Arch Dermatol 1996;132:519-526 ( selected for reprinting in international

edition and AMA Archives Journals Abstracts, JAMA 1997; 277:360e )

Sewon Kang, M.D.

32. Elder JT, Kaplan A, Cromie MA, Kang S, Voorhees JJ: Retinoid induction of CRABP-II

mRNA in human dermal fibroblasts: Use as a retinoid bioassay. J Invest Dermatol

1996;106:517-521

33. Kang S, Li XY, Voorhees JJ: Pharmacology and molecular action of retinoids and

vitamin D in skin. J Invest Dermatol Symposium Proceedings 1996;1:15-21

34. Kurlandsky SB, Duell EA, Kang S, Voorhees JJ, Fisher GJ: Auto-regulation of retinoic

acid biosynthesis through regulation of retinol esterification in human keratinocytes.

J Biol Chem 1996; 271:15346-15352

35. Fader DJ, Kang S: Calciphylaxis without renal failure. Arch Dermatol 1996; 132:837-

838

36. Kang S, Duell EA, Kim KJ, Voorhees JJ: Liarozole inhibits human epidermal retinoic

acid 4-hydroxylase activity and differentially augments human skin responses to retinoic

acid and retinol in-vivo. J Invest Dermatol 1996;107:183-187

37. Duell EA, Derguini F, Kang S, Elder JT, Voorhees JJ: Extraction of human skin

epidermis treated with retinol yields retro retinoids in addition to free retinol and retinyl

esters. J Invest Dermatol 1996;107:178-182

38. Loo DS, Kang S: Diffuse normolipemic plane xanthomas with monoclonal gammopathy

presenting as urticarial plaques. J Am Acad Dermatol 1996;35:829-832

39. Chen GF, Kang K, Kang S, Rook AH, Kubin M, Voorhees JJ, Cooper KD:

Differential induction of IL-12 p40 and IL-10 mRNA in human Langerhans‟ cells and

keratinocytes by in-vivo occlusion, vehicle and all-trans retinoic acid. J Cutan Med

Surg 1996;1:74-80

40. Choi J-H, O'Conner TP, Kang S, Voorhees JJ, Fisher GJ: Activation of ribosomal

protein S6 kinase in psoriatic lesions and cultured human keratinocytes by epidermal

growth factor receptor ligands. J Invest Dermatol 1997;108:98-102

41. Karimipour D, Johnson TM, Kang S, Wang TS, Lowe L: Mucinous carcinoma of the

skin. J Am Acad Dermatol, 1997;36:323-326

42. Kang S, Li XY, Duell EA, Voorhees JJ: The retinoid-X-receptor agonist 9-cis-retinoic

acid and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25-

dihydroxyvitamin D3 in human skin in-vivo. J Invest Dermatol 1997;108:513-518

( Selected for In This Issue )

43. Javier AF, Bata-Csorgo Zs, Ellis CN, Kang S, Voorhees JJ, Cooper KD: Rapamycin

(Sirolimus) inhibits proliferating cell nuclear antigen expression and arrests cell cycle in

the G1 phase in human keratinocyte stem cells. J Clin Invest 1997;99:2094-2099

44. Kang S: Metabolism and molecular action of retinoid in human skin. Clin Dermatol

(Seoul) 1997;3:8-10

Sewon Kang, M.D.

45. Duell EA, Kang S, Voorhees JJ: Unoccluded retinol penetrates human skin in vivo more

effectively than unoccluded retinyl palmitate or retinoic acid. J Invest Dermatol

1997;109:301-305

46. Kang S, Fisher GJ, Voorhees JJ: Photoaging and topical tretinoin: therapy, pathogenesis,

and prevention. Arch Dermatol 1997;133:1280-1284

47. Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ: Pathophysiology of

premature skin aging induced by ultraviolet light. N Engl J Med 1997;337:1419-28

48. Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, Ulyanov G, Gadgil SD,

Tanase A, Lawrence I, Scotellaro P, Raye K, Bekersky I: Tacrolimus (FK-506) ointment

for atopic dermatitis: A phase I study in adults and children. J Am Acad Dermatol

1998;38:69-76

49. Kang S, Yi S, Griffiths CEM, Fancher L, Hamilton TA, Choi JH: Calcipotriene-induced

improvement in psoriasis is associated with reduced interleukin-8 and increased

interleukin-10 levels within lesions. Br J Dermatol 1998;138:77-83

50. Fisher GJ, Talwar H, Lin J, Lin P, McPhillips F, Wang ZQ, Li XY, Wan Y, Kang S,

Voorhees JJ: Retinoic acid inhibits induction of c-JUN protein by ultraviolet radiation

that occurs subsequent to activation of mitogen-activated protein kinase pathways in

human skin in-vivo. J Clin Invest 1998;101:1432-1440 (All authors contributed equally

to this work)

51. Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D and 27 collaborating

investigators ( S Kang ): Once-weekly fluconazole (150, 300, or 450 mg) in the

treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol

1998;38:S87-94

52. Ling MR, Swinyer LJ, Jarratt MT, Falo L, Monroe EW, Tharp M and 23 collaborating

investigators ( S Kang ): Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of

treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol

1998;38:S95-102

53. Savin RC, Drake L, Babel D, Stewart DM, Rich P, Ling MR and 29 collaborating

investigators ( S Kang ): Pharmacokinetics of three once-weekly dosages of fluconazole

(150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad

Dermatol 1998;38:S110-116

54. Musial J, Gluszko P, Undas A, Mahdi F, Kang S, Szczeklik A, Schmaier AH: Gamma

interferon administration to patients with atopic dermatitis inhibits fibrinolysis and

elevates C1 inhibitor. Thrombosis Research 1998;89:253-261

55. Koo J, Abrams B, Albrecht G, Altmeyer P, Bahmer FA, Belaich S and 45 collaborating

investigators ( S Kang ): A randomized, double-blind study comparing the efficacy,

safety, and optimal dose of two formulations of cyclosporin in patients with severe

psoriasis. Br J Dermatol 1998;139:88-95

Sewon Kang, M.D.

56. Kang S, Voorhees JJ: Photoaging therapy with topical tretinoin: an evidence-based

analysis. J Am Acad Dermatol 1998;39:S55-61

57. Kang S: Topical tretinoin therapy for management of early striae. J Am Acad Dermatol

1998;39:S90-92

58. Varani J, Fisher GJ, Kang S, Voorhees JJ: Molecular mechanisms of intrinsic skin aging

and retinoid-induced repair and reversal. J Invest Dermatol Symposium Proceedings

1998;3:57-60

59. Varani J, Kang S, Stoll S, Elder JT: Human psoriatic skin in organ culture: comparison

with normal skin exposed to exogenous growth factors and effects of an antibody to the

EGF receptor. Pathobiol 1998;66:253-259

60. Wang ZQ, Boudjelal M, Kang S, Voorhees JJ, Fisher GJ: Ultraviolet irradiation of

human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid

pre-treatment. Nature Medicine 1999;5:418-422

61. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A,

Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry K,

Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S: CTLA4Ig-mediated blockade of

T cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-

1252

62. Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D and 18 collaborating

investigators ( S Kang): Finasteride in the treatment of men with frontal male pattern

hair loss. J Am Acad Dermatol 1999;40:930-937

63. Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, Kang S, Fisher GJ, Voorhees JJ:

1,25-dihydroxyvitamin D3 increases nuclear vitamin D receptors by blocking

ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrin

1999;13:1686-1694

64. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ: 1,25-Dihydroxycholecalciferol and

cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts

transplanted onto SCID mice. J Invest Dermatol 1999;113:1082-1089

65. Varani J, Warner RL, Gharaee-Kermani M, Phan SH, Kang S, Chung JH, Wang ZQ,

Datta SC, Fisher GJ, Voorhees JJ: Vitamin A antagonizes decreased cell growth and

elevated collagen-degrading matrix metalloproteinases and stimulates collagen

accumulation in naturally aged human skin. J Invest Dermatol 2000;114:480-486

66. Chung JH, Kang S, Varani J, Lin J, Fisher GJ, Voorhees JJ: Decreased extracellular-

signal-regulated kinase and increased stress-activated MAP kinase activities in aged

human skin in vivo. J Invest Dermatol 2000;115:177-182

67. Fisher GJ, Datta S, Wang ZQ, Li XY, Quan T, Chung JH, Kang S, Voorhees JJ: c-Jun-

dependent inhibition of cutaneous procollagen transcription following ultraviolet

irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000;106:663-670

Sewon Kang, M.D.

68. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo

CA, Jegasothy BV, Linsley PS, Krueger JG: Blockade of T lymphocyte costimulation

with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses

the cellular pathology of psoriatic plaques, including the activation of keratinocytes,

dendritic cells, and endothelial cells. J Exp Med 2000;192:681-693

69. Gottlieb A, Krueger J, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M,

Wittkowski K, Ochs H, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M: Effects of

administration of a single dose of a humanized monoclonal antibody to CD11 on the

immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-435

70. Fleischer AB, Schwartzel EH, Colby SI, Altman DJ, and 32 collaborating investigators

( S Kang ): The combination of 2% 4-hydroxyanisole and 0.01% tretinoin is effective in

improving solar lentigines and related hyperpigmented lesions in two double-blind

multicenter clinical studies. J Am Acad Dermatol 2000;42:459-467

71. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM: Long-term safety and efficacy

of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad

Dermatol 2001;44:S58-S64

72. Varani J, Spearman D, Perone P, Fligiel SEG, Datta SC, Wang ZQ, Shao Y, Kang S,

Fisher GJ, Voorhees JJ: Inhibition of type I procollagen synthesis by damaged collagen

in photoaged skin and by collagenase-degraded collagen in vitro. Am J Pathol

2001;158:931-942

73. Watson REB, Craven NM, Kang S, Kielty CM, Griffiths CEM: A short-term screening

assay, using fibrillin-1 as a reporter molecule, for photoaging repair agents. J Invest

Dermatol 2001;116:672-678

74. Fisher GJ, Choi HC, Bata-Csorgo Z, Shao Y, Datta S, Wang ZQ, Kang S, Voorhees JJ:

Ultraviolet irradiation increases matrix metalloproteinase-8 protein in human skin in vivo.

J Invest Dermatol 2001;117:219-226

75. Bezanis GJ, Choi JH, Kang S: Immunomodulatory effects of vitamin D analogues in

psoriatic skin. Ann Dermatol 2001;13:201-204

76. Kang S, Leyden JJ, Lowe NJ, Ortonne JP, Phillips TJ, Weinstein GD, Lew-Kaya DA,

Matsumoto RM, Sefton J, Walker PS, Gibson JR: Tazarotene cream for the treatment of

facial photodamage: A multicenter, investigator-masked, randomized, vehicle-

controlled, parallel comparison of tazarotene 0.01%, 0.025%, 0.05%, and 0.1% creams

and tretinoin 0.05% emollient cream applied once-daily for 24 weeks. Arch Dermatol

2001;137:1597-1604

77. Thiboutot D, Gold M, Jarratt M, Kang S, Kaplan D, Millikan L, Wolfe J, Loesche C,

Baker M: Randomized, controlled trial of the tolerability, safety and efficacy of

adapalene gel 0.1% and tretinoin microsphere gel 0.1% in the treatment of acne vulgaris.

Cutis 2001;68:10-19

78. Wolf JE, Taylor JR, Tschen E, Kang S: Topical 3.0% diclofenac in 2.5% hyaluronic

acid gel in the treatment of actinic keratoses. Intl J Dermatol 2001;40:709-713

Sewon Kang, M.D.

79. Varani J, Zeigler M, Dame MK, Kang S, Fisher GJ, Voorhees JJ, Stoll SW, Elder JT:

Heparin-binding epidermal-growth-factor-like growth factor activation of keratinocyte

ErbB receptors mediates epidermal hyperplasia, a prominent side-effect of retinoid

therapy. J Invest Dermatol 2001;117:1335-1341

80. Lebwohl M, Elewski B, Eisen D, Savin RC and 11 collaborating investigators (S Kang):

Efficacy and safety of terbinafine (Lamisil®) 1% solution in the treatment of interdigital

tinea pedis and tinea corporis/cruris. Cutis 2001;67:261-266

81. Quan T, He T, Kang S, Voorhees JJ, Fisher GJ: Connective tissue growth factor:

expression in human skin in vivo and inhibition by ultraviolet irradiation. J Invest

Dermatol 2002;118:402-8

82. Quan T, He T, Kang S, Voorhees JJ, Fisher GJ: Ultraviolet Irradiation alters

Transforming Grown Factor /Smad Pathway in Human Skin in vivo. J Invest Dermatol

2002;119:499-506

83. Chung JH, Seo JY, Lee MK, Lee JH, Kang S, Fisher GJ, and Voorhees JJ: Ultraviolet

modulation of human macrophage metalloelastase in human skin in vivo. J Invest

Dermatol 2002;119:507-512

84. Fisher GJ, Kang S: Phototherapy for scleroderma: biological rationale, results and

promise. Curr Opin Rheumatol 2002;14:723-726

85. Fisher GJ, Kang S, Varani J, Zsuzsanna BC, Wan Y, Datta S, Voorhees JJ: Mechanisms

of photoaging and chronological skin aging. Arch Dermatol 2002;138:1462-1470

86. Kang S, Chung JH, Lee JH, Fisher GJ, Duell EA, Voorhees JJ: Topical N-acetyl

cysteine and genistein inhibit ultraviolet signaling that leads to photoaging in human skin

in vivo. J Invest Dermatol 2003;120: 835-841

87. Fligiel SEG, Varani J, Datta SC, Kang S, Fisher GJ, Voorhees JJ: Collagen degradation

in aged/photodamaged skin in vivo and after exposure to matrix metalloproteinase-1 in

vitro. J Invest Dermatol 2003;120:842-848

88. Kang S, Paller A, Soter N, Satoi Y, Rico MJ, Hanifin JM. Safe treatment of head/neck

AD with Tacrolimus ointment. J Dermatol Treat 2003;14:86-94

89. Kang S, Goldfarb M, Weiss J, Metz R, Hamilton TA, Voorhees JJ, Griffiths CEM:

Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a

randomized trial. J Am Acad Dermatol 2003;49:83-90

90. Brennan M, Bhatti H, Nerusu KC, Bhagavathula N, Kang S, Varani J, Voorhees JJ.

Matrix metalloproteinase-1 is the major collagenolytic enzyme responsible for collagen

damage in UV-irradiated human skin. Photochem Photobiol 2003;78:43-48

91. Chung JH, Hanft VN, Kang S: Aging and photoaging. J Am Acad Dermatol

2003;49:690-697

Sewon Kang, M.D.

92. Petro A, Crofford L, Kang S: Infliximab: effective therapy for pustular psoriasis. Ann

Dermatol 2003;15:149-150

93. Gottlieb A, Matheson R, Lowe N, Krueger G, Kang S, Goffe B, Gaspari A, Ling M,

Weinstein G, Nayak A, Gordon K, Zitnik R. A randomized trial of etanercept as

monotherapy for psoriasis. Arch Dermatol 2003;139:1627-1632

94. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik, BR, Margolis DJ, Schachner LA,

Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic

dermatitis. J Am Acad Dermatol 2004;50:391-404

95. Leyden J, Bergfeld W, Drake L, Dunlap F, and 30 collaborating investigators (S Kang).

A systemic type I 5 α-reductase in the treatment of acne vulgaris. J Am Acad Dermatol

2004;50:443-447

96. Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, AbdulGhani AA, Goldfarb M,

Chieffo N, Totoritis MC: Evaluation of safety and clinical activity of multiple doses of

the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe

plaque psoriasis. Clin Immuno 2004;111:28-37

97. Orringer JS, Kang S, Hamilton T, Schumacher W, Cho S, Hammerberg C, Fisher GJ,

Karimipour DJ, Johnson TM, Voorhees JJ. Treatment of acne vulgaris with a pulsed dye

laser: a randomized controlled trial. JAMA 2004;291:2834-2839 (first two authors

contributed equally to this work)

98. Orringer JS, Kang S, Johnson TM, Fisher GJ, Voorhees JJ. Pulsed dye laser treatment of

acne vulgaris. [letter] JAMA 2004;292:1430

99. Lowe NJ, Gifford M, Tanghetti E, Poulin YP, Goldman M, Tse Y, Yamauchi P,

Rosenzweig H, Kang S. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream

in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized,

parallel-group study. J Cosmet Laser Ther 2004;6:79-85

100. Varani J, Schuger L, Dame MK, Leonard C, Fligiel SEG, Kang S, Fisher GJ, Voorhees

JJ. Reduced fibroblast interaction with intact collagen as a mechanism for depressed

collagen synthesis in photodamaged skin. J Invest Dermatol 2004;122:1471-1479

101. Quan T, He T, Kang S, Voorhees, J, Fisher G. Solar ultraviolet irradiation reduces

collagen in photoaged human skin by blocking transforming growth factor- type II

receptor/Smad signaling. Am J Pathol 2004;165:741-751

102. Orringer J, Johnson T, Kang S, Karimipour D, Hammerberg C, Hamilton T, Voorhees JJ,

Fisher GJ. Effect of carbon dioxide laser resurfacing on epidermal p53 immunostaining

in photodamaged skin. Arch Dermatol 2004;140:1073-1077

103. Kafi R, Fisher G, Quan T, Shao Y, Wang R, Voorhees JJ, Kang S. Ultraviolet A1

phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol

2004;140:1322-1324

Sewon Kang, M.D.

104. Orringer JS, Kang S, Johnson TM, Karimipour DJ, Hammerberg C, Voorhees JJ, Fisher

GJ. Connective tissue remodeling induced by CO2 laser resurfacing of photodamaged

human skin. Arch Dermatol 2004;140:1326-1332

105. Rich P, Tschen EH, Jones T, Menter A, Lowe NJ, Eichenfield L, Hebert AA, Pariser D,

Savin RP, Smith SR, Jarratt M, Rodriguez D, Chalker DK, Kempers S, Ling M, Rafal

ES, Sullivan S, DiGiovanna JJ, Kang S, Shah LP, Wu E, Eberhardt DR, Chin C,

Ondovik M, Pak J, Bryce GF, and Khoo K-C: Effect of a single course of isotretinoin

therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular

acne. J Am Acad Dermatol 2004;51:709-717

106. Kang S, Krueger G, Tanghetti E, Lew-Kaya D, Pharm D, Sefton J, Walker P, Gibson J:

A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment

of photodamage. J Am Acad Dermatol 2005;52:268-274

107. Karimipour D, Kang S, Johnson T, Orringer J, Hamilton T, Hammerberg C, Voorhees JJ,

Fisher GJ. Microdermabrasion: a molecular analysis following a single treatment. J Am

Acad Dermatol 2005;52:215-223

108. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis supprativa with infliximab in a

patient with Crohn‟s disease. J Dermatol Treatment 2005;16:58-62

109. Varani J, Bhagavathula N, Scherzer H, Fay K, Boitano A, Glick G, Johnson K, Kang S,

Opipari A: A novel benzodiazepine selectively inhibits keratinocyte proliferation and

reduces retinoid-induced epidermal hyperplasia in organ-cultured human skin. J

Pharmacol Exp Ther 2005;313:56-63

110. Kang S, Cho S, Chung JH, Fisher GJ, Voorhees JJ. Inflammation and extracellular

matrix degradation mediated by activated transcription factors NFkB and AP-1 in

inflammatory acne lesions in vivo. Am J Pathol 2005;166:1691-1699

111. Kang S, Bergfeld W, Gottlieb A, Hickman J, Humeniuk J, Kempers S, Lebwohl M,

Lowe N, McMichael A, Milbauer J, Phillips T, Powers J, Rodriguez D, Savin R, Shavin

J, Sherer D, Silvis N, Weinstein R, Weiss J, Nighland M, Grossman R, Nyirady J. Long

term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of

photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin

Dermatol 2005; 6: 245-253.

112. Cho S, Lowe L, Hamilton TA, Fisher GJ, Voorhees JJ, Kang S. Long term treatment of

photoaged human skin with topical retinoic acid improves epidermal cell atypia and

thickens collagen band in the papillary dermis. J Am Acad Dermatol 2005; 53:769-774.

113. Orringer J, Voorhees JJ, Hamilton T, Hammerberg C, Kang S, Johnson T, Karimipour D,

Fisher G. Dermal matrix remodeling following non-ablative laser therapy. J Am Acad

Dermatol 2005; 53:775-782.

114. Thiboutot D, Shalita A, Yamauchi P, Dawson C, Arsonnaud S, Kang S. Combination

therapy with adapalene gel 0.1% & doxcycline for severe acne vulagaris: A randomized

controlled study. SKINmed 2005; 4:138-146.

Sewon Kang, M.D.

115. Karimipour DJ, Kang S, Johnson TM, Orringer JS, Hamilton T, Hammerberg C,

Voorhees JJ, Fisher G. Microdermabrasion with and without aluminum oxide crystal

abrasion: A comparative molecular analysis of dermal remodeling. J Am Acad Dermatol

2006; 54:405-410.

116. Thiboutot D, Shalita A, Yamauchi P, Dawson C, Kerrouche N, Arsonnaud S, Kang S.

Adapalene gel 0.1% as maintenance therapy for acne vulgaris: a randomized, controlled,

investigator-blind follow-up of a recent combination study. Arch Dermatol 2006;

142:597-602.

117. Friedrich M, Bock D, Philipp S, Ludwig N, Sabat R, Wolk K, Schröter-Maas S, Aydt E,

Kang S, Dam T, Zahlten R, Sterry W, Wolff G. Pan-selectin antagonism improves

psoriasis manifestation in mice and man. Arch Dermatol Res 2006; 297:345-351.

118. Rittié L, Varani J, Kang S, Voorhees JJ, Fisher G. Retinoid-induced epidermal

hyperplasia is mediated by epidermal growth factor receptor activation via specific

induction of its ligands heparin binding-EGF and amphiregulin in human skin in vivo. J

Invest Dermatol 2006; 126:732-739.

119. Varani J, Dame M, Rittie L, Fligiel SEG, Kang S, Fisher G, Voorhees JJ. Decreased

collagen production in chronologically aged skin: Roles of age-dependent alteration in

fibroblast function and defective mechanical stimulation. Am J Pathol 2006; 168:1861-

1868.

120. Quan T, He T, Shao Y, Lin L, Kang S, Voorhees JJ, Fisher G. Elevated cysteine-rich 61

mediates aberrant collagen homeostasis in chronologically aged and photoaged skin. Am

J Pathol 2006; 169:482-490.

121. Orringer J, Hammerberg C, Lowe L, Kang S, Johnson TM, Hamilton T, Voorhees JJ,

Fisher G. The effects of laser-mediated hair removal on the immunohistochemical

staining. J Am Acad Dermatol 2006; 55:402-407.

122. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Hammerberg C, Fisher GJ, Voorhees

JJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic

acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007;

143:155-163.

123. Orringer JS, Kang S, Maier L, Johnson TM, Sachs DL, Karimipour DJ, Helfrich YR,

Hamilton T, Voorhees JJ. A randomized, controlled, split-face clinical trial of 1320 nm

Nd:YAG laser therapy in the treatment of acne vulgaris. J Am Acad Dermatol 2007;

56:432-438.

124. Helfrich YR, Yu L, Ofori A, Hamilton TA, Lambert J, King A, Voorhees JJ, Kang S.

Effect of smoking on aging of photoprotected skin: Evidence gathered using a new

photonumeric scale. Arch Dermatol 2007; 143:397-402. [Erratum Arch Dermatol 2007;

143:633]

125. Schauber J, Dorschner RA, Coda AB, Büchua AS, Liu PT, Kiken D, Helfrich YR, Kang

S, Elalieh HZ, Steinmeyer A, Zügel U, Bikle DD, Modlin RL, Gallo RL. Injury enhances

Sewon Kang, M.D.

TLR2 function and antimicrobial peptide expression through a Vitamin D-dependent

mechanism. J Clin Invest 2007; 117:803-811.

126. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A

randomized, open-label trial of continuous versus interrupted etanercept therapy in the

treatment of psoriasis. J Am Acad Dermatol 2007; 56:598-603.

127. Helfrich YR, Kang S, Voorhees JJ. Topical becocalcidiol for the treatment of psoriasis

vulgaris: a randomized, placebo-controlled, double-blind, multi-center study. Br J

Dermatol 2007;157:369-374

128. Cowen EW, Liu C, Steinberg SM, Kang S, Vonderheid EC, Kwak HSR, Booher S,

Petricoin EF, Liotta LA, Whiteley G, Hwang ST. Differentiation of tumor-phase mycosis

fungoides, psoriasis vulgaris, and normal controls in a pilot study using serum proteomic

analysis. Br J Dermatol 2007; 157: 946-953

129. Kafi R, Kwak HSR, Schumacher W, Cho S, Hanft VN, Hamilton TA, King AL, Neal JD,

Varani J, Fisher G, Voorhees JJ, Kang S. Improvement of naturally aged skin with

vitamin A (retinol). Arch Dermatol 2007; 143:606-612.

130. Liu C, Shea N, Rucker S, Harvey L, Russo P, Saul R, Lopez M, Mikulskis A, Kuzdzal S,

Golenk E, Vonderheid E, Kang S, Cowen E, Hwang S, Whiteley G. Proteomic patterns

for classification of ovarian cancer and CTCL serum samples utilizing peak pairs

indicative of post-translational modifications. Protemics. 2007;22:4045-52

131. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M,

Kang S. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne

vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad

Dermatol 2007;57:791-9

132. Bahagavthula N, Nerusu K, Hanosh A, Aslam M, Sundberg T, Opipari A, Johnson K,

Kang S, Glick G, Varani J. Bz-423, a novel benzodiazepine, suppresses keratinocyte

proliferation and has anti-psoriatic activity in the human skin-SCID mouse transplant

model. J Pharmaco Exp Ther 2008; 324:938-947

133. Do TT, Zarkhin S, Orringer JS, Nemeth S, Hamilton TA, Sachs D, Voorhees JJ, Kang S.

Computer-assisted alignment and tracking of acne lesions indicate that most

inflammatory lesions arise from comedones and de novo. J Am Acad Dermatol 2008;

58: 603-608

134. Varani J, Perone P, Warner R, Dame M, Kang S, Fisher G, Voorhees J. Vascular tube

formation on matrix metalloproteinase-1-damaged collagen. Br J Cancer 2008;98:

1646-52

135. Wang F, Garza LA, Cho S, Kafi R, Hammerberg C, Quan T, Hamilton TA, Mayes M,

Ratanatharathorn V, Voorhees JJ, Fisher GJ, Kang S. Increased pigmentation diminishes

anti-fibrotic response of human skin to ultraviolet A1 phototherapy. Arch Dermatol

2008; 144:851-858

Sewon Kang, M.D.

136. Rittie L, Kang S, Voorhees J, Fisher G. Topical 17-estradiol stimulates collagen

production in sun-protected skin, but not in photoaged human skin in vivo. Arch

Dermatol 2008;144(9):1129-40

137. Orringer J, Hammerberg C, Hamilton T, Johnson T, Kang S, Sachs D, Fisher G,

Voorhees J. Molecular effects of photodynamic therapy for photoaging. Arch Dermatol

2008; 144:1296-1302

138. Wang F, Kwak HR, Elbuluk N, King AL, Hamilton TH, Duell EA, Voorhees J, Fisher G,

Kang S. Correlation of CYP26 inducibility with clinical response to isotretinoin. J Am

Acad Dermatol 2009;61(2):252-258

139. Sachs DL, Kang S, Hammerberg C, Helfrich Y, Karimipour D, Orringer J, Johnson T,

Hamilton T, Fisher G, Voorhees J. The effects of Topical 5-fluorouracil improves actinic

keratoses and photoaged skin: clinical and molecular analysis. Arch Dermatol 2009;

145(6):659-666

140. Rittie L, Stoll S, Kang S, Voorhees J, Fisher G. Hedgehog signaling maintains hair

follicle stem cell phenotype in young and aged human skin. Aging Cell 2009; 8:738-751

141. Fisher G, Quan T, He T, Shao Y, Cho M, Varani J, Kang S, Voorhees J. Collagen

fragmentation promotes oxidative stress and elevates matrix metalloproteinase-1 in

fibroblasts in aged human skin. Am J Pathol 2009;174:101-14

142. Do T, Bailey E, Wang F, Smith N, Lee W, Fisher G, Voorhees J, Kang S. Targeted

broadband UVB phototherapy improves disorders characterized by increased dermal

matrix. Br J Dermatol 2009;161:1405-1407

Accepted for Publication

143. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M,

Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Chen DM. Clinical response to

adalimumab treatment in moderate to severe psoriasis patients: double-blind, randomized

clinical trial and open-label extension study. J Am Acad Dermatol.

144. Quan T, Qin Z, Xu Y, He T, Kang S, Voorhees J, Fisher G. Ultraviolet Irradiation

Induces CYR61/CCN1, A Novel Mediator of Collagen Hemeostasis, via Activation of

Transcription Factor AP-1 in Human Skin Fibroblasts. J Invest Dermatol

Submitted for Publication

145. Kang S, Voorhees JJ. Future Perspectives for Clinical Investigation with RAMBAs.

146. Phillips T, Goldman M, Kang S, Lee P, Stromberg K, Mann M, Lee J. A cosmetic

outcome scale to assess irregular skin pigmentation and wrinkling severity.

147. Garza LA, Wang F, Fisher GJ, Cho S, Kafi R, Mayes M, Ratanatharathorn V, Voorhees

JJ, Kang S. Ultraviolet A1 therapy for fibrotic skin conditions.

Sewon Kang, M.D.

148. Abad-Casintahan F, Chow S, Goh C, Kubba R, Leung R, Miyachi Y, Noppakun N, See J,

Suh D, Yang L, Kang S. Toward evidence-based practice in acne: consensus of asian

working group.

149. Elmets C, Viner J, Pentland A, Cantrell W, Bailey H, Kang S, Linden K, Hefferman M,

Duvie M, Elewski B, Umar A, Lin H, Bell W, Gordon G. Chemoprevention of Non-

Melanoma Skin Cancer with Celecoxib.

Non-Peer Reviewed Publications

150. Kang S, Sober AJ: Childhood melanoma. The Melanoma Letter, 1991;9:1

151. Kang S: Computers in the evaluation of pigmented lesions. The Skin Cancer

Foundation Journal, 1992;10:35

152. Kang S: Calcipotriene: A modern psoriasis medicine with ties to rickets. J Geriatr

Dermatol 1995; 3SB:28B-32B

153. Kang S: Photoaging and tretinoin. Dermatologic Clinics, 1998;16:357-364

154. Johnson TM, Sondak VK, Su LD, Headington JT, Kang S, Lowe L: Is it a benign spitz

nevus or a malignant melanoma? Primary Care & Cancer, 2000;20:41-44

CHAPTERS IN BOOKS & EDITED SPECIAL JOURNAL ISSUES

1. Kang S, Serri F, Sober AJ: Regressing Melanoma and Depigmentation, in Cascienelli N,

Santinami M, Veronesi U (editors) Cutaneous Melanoma Biology and Management.

Milano, Masson, 1990;159-166

2. Kang S, Milton GW, Sober AJ: Childhood Melanoma, in Balch CM, Sober AJ (editors)

Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide (2nd.

edition). Philadelphia, JB Lippincott Co., 1992;312-318

3. Kang S, Sober AJ: Pigmentary Disorders, in Rakel R (editor) Conn's Current Therapy,

1992 Edition. Philadelphia, WB Saunders, 1992;793-796

4. Sober AJ, Kang S, Barnhill RL: Discerning Individuals at Elevated Risk for Cutaneous

Melanoma, in Rampen FHJ (editor) Clinics in Dermatology, 1992;9:15-20

5. Kang S: Seborrheic Dermatitis, in Arndt KA, et al. (editors) Manual of Clinical

Problems in Dermatology. Boston, Little, Brown and Company, 1992;77-81

6. Kang S: Pyoderma, in Arndt KA, et al. (editors) Manual of Clinical Problems in

Dermatology. Boston, Little, Brown and Company, 1992;137-142

7. Kang S: Pyoderma Gangrenosum, in Arndt KA, et al. (editors) Manual of Clinical

Problems in Dermatology. Boston, Little, Brown and Company, 1992;300-303

Sewon Kang, M.D.

8. Kang S, Sober AJ: Disturbances in Melanin Pigmentation, in Moschella SL, Hurley H

(editors) Dermatology (3rd. edition). Philadelphia, WB Saunders, 1992;2:1442-1474

9. Kang S, Lerner EA, Sober AJ, Levine N: Pigmentary Disorders from Exogenous

Causes, in Levine N, Maibach HI (editors) Pigmentation and Pigmentary Disorders.

Boca Raton, CRC Press, Inc., 1993;417-438

10. Kang S, Griffiths CEM, Voorhees JJ: Photoaging: Mechanisms of retinoic acid-induced

improvement, in Bernard BA, Shroot B (editors) From Molecular Biology to

Therapeutics, Pharmacology and the Skin. Basel, Karger Series, 1993;5:40-45

11. Kang S, Voorhees JJ: Topical retinoids, in Freedberg IM, Eisen AZ, Wolff K, Austen

KF, Goldsmith LA, Katz SI, Fitzpatrick TB (editors) Fitzpatrick's Dermatology in

General Medicine (fifth edition) McGraw-Hill, 1998;2726-2733

12. Kang S, Voorhees JJ: Immunopathogenesis of psoriasis, in van de Kerkhof P (editor)

Textbook of Psoriasis. Oxford, Blackwell Science, 1999;106-118.

13. Kang S, Voorhees JJ: Retinoids in psoriasis, in Christophers E, Wolff K (editors)

Dermatologic Therapy (a special issue on The Treatment of Psoriasis). Copenhagen,

Munksgaard, 1999;11:67-74

14. Chung JH, Kang S, Fisher GJ: The molecular mechanisms of retinoid effects in human

skin, Clinics in Dermatology. Advances in Dermatology, 1999;15:367-393

15. Kang S, Fisher GJ, Voorhees JJ: Pharmacology and molecular mechanisms of retinoid

action in skin, in Livrea MA (editor) Vitamin A and Retinoids: An Update of Biological

Aspects and Clinical Applications (Molecular and Cell Biology Update). Basel,

Birkhauser, 2000;151-159

16. Kang S: Interaction of vitamin D and retinoids, in Kragballe K (editor) Vitamin D in

Dermatology. New York, Marcel Dekker, 2000;157-167

17. Sachs D, Baur S, Kang S: Topical vitamin D, in Wolverton SE (editor) Comprehensive

Dermatologic Drug Therapy. Philadelphia, WB Saunders Co, 2001;685-694

18. Kang S, Fisher GJ, Voorhees JJ: Photoaging: pathogenesis, prevention and treatment, in

Gilchrest BA (editor) Geriatric Dermatology, Clinics in Geriatric Medicine.

Philadelphia, WB Saunders Co, 2001,17:643-659

19. Kang S, Voorhees JJ: Topical retinoids, in Freedberg IM, Eisen AZ, Wolff K, Austen

KF, Goldsmith LA, Katz SI, Fitzpatrick TB (editors) Fitzpatrick's Dermatology in

General Medicine (sixth edition) McGraw-Hill, 2003;2328-2334

20. Kang S, Cho S, Voorhees JJ: Immunopathogenesis of psoriasis, in van de Kerkhof P

(editor) Textbook of Psoriasis (second edition). Oxford, 2003; 110-123

21. Chung JH, Cho S, Kang S: Why does the skin age? Intrinsic aging, photoaging, and

their pathophysiology, in Rigel D, Weiss B, Lim H, Dover J (editors) Photoaging.

Marcel Dekker, 2004; 1-13

Sewon Kang, M.D.

22. Kang S (Guest Editor): An update on the use of retinoids in dermatology. Dermatologic

Therapy. Munksgaard Ltd, 2006; 19(5): September/October

23. Rosi Y, Sachs D, Kang S: Topical vitamin D, in Wolverton SE (editor) Comprehensive

Dermatologic Drug Therapy (2nd Edition). Philadelphia, WB Saunders Co, 2007; 691-

699

24. Kang S, Voorhees JJ: Topical retinoids, in Wolff K, Goldsmith LA, Katz SI, Gilchrest

B, Paller AS, Leffell DJ (editors) Fitzpatrick's Dermatology in General Medicine

(seventh edition), McGraw-Hill, 2008; 2106-2112

PRESENTATIONS: INTERNATIONAL

1. Computerized digital photography in the pigmented lesions clinic. Clinical Dermatology

in the Year 2000, London, May 1990

2. Melanoma and melanoma precursors - pigment pattern characterization in vivo using

computer-assisted epiluminescence microscopy. XIV th International Pigment Cell

Conference, Kobe, Japan, October 1990

3. Identification of populations-at-risk for melanoma and epithelial skin cancer using skin

phototyping. European Society for Pigment Cell Research, Amsterdam, September 1991

4. Natural history and prognosis of cutaneous melanoma. The 7th Korea-Japan Joint

Meeting of Dermatology, Seoul, Korea, October 1991

5. Childhood melanoma and Spitz nevi. Advances in the Biology and Clinical Management

of Melanoma, Houston, November 1991

6. Paraneoplastic pemphigus in Waldenstrom's macroglobulinemia. 18th World Congress

of Dermatology, New York, June 1992

7. Identification of populations-at-risk for melanoma and epithelial skin cancer using skin

phototyping. 18th World Congress of Dermatology, New York, June 1992

8. Digital imaging and epiluminescence microscopy. 18th World Congress of Dermatology,

New York, June 1992

9. Melanoma screening with digital epiluminescence microscopy. Third International

Conference on Melanoma, Venice, Italy, March 1993

10. Skin phototype and melanoma. Third International Conference on Melanoma, Venice,

Italy, March 1993

11. Retinol elicits epidermal acanthosis and CRABP-II mRNA expression, but insignificant

erythema when topically applied to human skin. The Second Tricontinental Meeting of

the JSID, SID and ESDR, Kyoto, Japan, October 1993

Sewon Kang, M.D.

12. Vitamins and hormones in the skin. Department of Dermatology, Asan Medical Center,

Ulsan University College of Medicine, Seoul, Korea, October 1993

13. Cutaneous effects of topical retinol in human skin. Department of Dermatology, Seoul

National University College of Medicine, Seoul, Korea, October 1993

14. Retinol applied to human skin in-vivo produces histologic and molecular changes

characteristic of retinoic acid exposure but without measurable retinoic acid increase or

irritation. American Association for Cancer Research, Special Conference on

Mechanism of Action of Retinoids, Vitamin D and Steroid Hormones, Whistler, Canada,

January 1995

15. Retinoid metabolism in human skin in-vivo. Department of Dermatology, Catholic

University Medical Center, Seoul, Korea, May 1995

16. Metabolism of vitamin D and its molecular mechanism of action in human skin.

Department of Dermatology, Ulsan University College of Medicine, Seoul, Korea, May

1995

17. Cytochrome P-450-mediated inactivation of retinoic acid in human skin. Department of

Dermatology, Kosin Medical College, Pusan, Korea, May 1995

18. Topical tretinoin (retinoic acid) improves early stretch marks. European Retinoid

Research Group. Sophia Antipolis, France, October, 1995

19. Pharmacokinetic findings from a topical FK-506 study in children with atopic dermatitis.

The Clinical Dermatology 2000, An International Congress, Vancouver, Canada, May

1996

20. Retinoic acid therapy of skin diseases. The Clinical Dermatology 2000, An International

Congress, Vancouver, Canada, May 1996

21. Calcipotriene treatment of psoriasis results in an early induction of interleukin-10 and a

concomitant reduction in interleukin-8 levels. Psoriasis: From Gene to Clinic, London,

UK, December 1996

22. Metabolism and molecular action of retinoids in human skin in-vivo. Department of

Dermatology, Seoul National University, College of Medicine, Seoul, Korea, January,

1997

23. Calcipotriene-induced improvement in psoriasis is causally associated with early

modulations of interleukins 10 and 8. 19th World Congress of Dermatology, Sydney,

Australia, June, 1997

24. Targeting cytochrome P-450 as an approach to safely deliver retinoid action to human

skin. Dermatology Update, Montreal, Canada, October, 1997

25. Enhancing retinoid and vitamin D3 effects by inhibiting the 4- and 24-hydroxylases.

Symposium on New Strategies in the Treatment of Skin Diseases- Focus on Cytochrome

P450, Cologne, Germany, May, 1998

Sewon Kang, M.D.

26. Glucocorticoid and retinoic acid inhibit UV irradiation induction of cytokine and matrix-

degrading metalloproteinase genes through distinct mechanisms in human skin in vivo.

International Investigative Dermatology, Cologne, Germany, May, 1998

27. Pharmacologic evidence for psoriasis as an immunological disease (Invited Plenary

Lecture). Korean Society for Psoriasis Research, Seoul, Korea, May, 1998

28. Skin aging- current concept and treatment (Invited Plenary Lecture). The 50th Annual

Meeting of the Korean Dermatological Association, Seoul, Korea, October, 1998

29. Photoaging- effective management based on patho-physiology. Third Annual

International Symposium on Aging Skin, San Francisco, California, January, 1999

30. Immunomodulatory effects of vitamin D analogues in psoriatic skin. Fourth International

Calcipotriol Symposium - Vitamin D in Dermatology, Barcelona, Spain, April, 1999

31. Evidence based management of aged and photoaged skin. Dermatology Update for the

Millennium, San Francisco, California, October, 1999

32. Cutaneous retinoid metabolism and its effect on vitamin D signaling. Athens

Dermatology Symposium: Modern Trends in Skin Pharmacology- Molecular and

Clinical Aspects, Athens, Greece, June 2000

33. Evidence-based therapy with retinoids in dermatology. Department of Dermatology,

University of Tokyo, Japan, August, 2000

34. Distinguishing the cutaneous effect and side-effect of topical retinoids. Department of

Dermatology, Kobe University, Kobe, Japan, August 2000

35. Evidence-based therapy with retinoids in dermatology. Keio University, Tokyo, Japan,

August 2000

36. Retinoid signaling in human skin in vivo (Invited Plenary Lecture). 25th

Annual Meeting

of the Japanese Society for Investigative Dermatology, Gifu, Japan, September, 2000

37. Adapalene gel for the treatment of actinic keratoses. Differin Five-Year Anniversary

Symposium, Cannes, France, October, 2000

38. Molecular dissection of retinoid dermatitis. Department of Dermatology, Seoul National

University, College of Medicine, Seoul, Korea, October, 2000

39. Retinoid signaling in human skin- adapalene‟s mode of action. The 52nd

Annual Meeting

of the Korean Dermatological Association, Seoul, Korea, October, 2000

40. Molecular basis for retinoid irritation. Department of Dermatology, Yonsei University,

College of Medicine, Seoul, Korea, October, 2000

41. Retinoids for aging skin. The 5th

International Symposium on Aging Skin, Coronado,

California, May, 2001

Sewon Kang, M.D.

42. Cytotoxic T lymphocyte associated antigen (CTLA)-4Ig. 2nd

Joint Meeting of

International Psoriasis Symposium and the European Congress on Psoriasis, San

Francisco, June, 2001

43. A new concept in acne pathophysiology – implications in treatment. The 12th

Japan-

Korea Joint Meeting of Dermatology, Tokyo, Japan, November, 2001

44. Randomized efficacy and safety assessment of adapalene gel (0.1% and 0.3%) and

vehicle for the treatment of actinic keratoses and lentigines. 20th

World Congress of

Dermatology, Paris, France, July 1, 2002

45. Current perspectives on acne inflammation and scarring. 20th

World Congress of

Dermatology, Paris, France, July 3, 2002

46. Nephrogenic fibrosing dermopathy: a new entity that responds to UVA1. Department of

Dermatology, Seoul National University, College of Medicine, Seoul, Korea, October 7,

2002.

47. Topical retinoids in the treatment of extrinsically aged skin. Symposium on advances in

topical and oral retinoid therapy for the treatment of acne, psoriasis and extrinsically aged

skin. International Investigative Dermatology, Miami, USA, May 1, 2003

48. Metabolism of retinoids in human skin in vivo. Asian Scientific Forum. International

Investigative Dermatology, Miami, USA, May 1, 2003

49. Ultraviolet A1 is an effective antibiotic phototherapy for scleroderma, and sclerodermoid

variant of chronic graft-versus-host disease. International Investigative Dermatology,

Miami, USA, May 3, 2003

50. Advances in intrinsic skin aging (Keynote lecture). 2003 International Federation of

Society of Cosmetic Chemist. Seoul, Korea, September 23, 2003

51. Intrinsic skin aging and its treatment with retinol. Department of Dermatology, Seoul

National University, College of Medicine, Seoul, Korea, September 23, 2003

52. Evidence for antioxidant usage in photoaging prevention. The 13th

Japan-Korea Joint

Meeting of Dermatology, Daejeon, Korea, October 9, 2003

53. Efficacy evaluation of antiwrinkle products in the USA. International Symposium on

Efficacy and Safety of Anti-wrinkle Cosmetics. Korea Food & Drug Administration,

Seoul, Korea, November 7, 2003

54. Advances in intrinsic skin aging. 18th

Brazilian Cosmetology Congress, Sao Paulo,

Brazil, May 11, 2004

55. UVA1 phototherapy for scleroderma. 10th

Hamchun Dermatological Symposium, Seoul

National University, Seoul, Korea, June 9, 2004

Sewon Kang, M.D.

56. Photoprotection in the prevention of photoaging: study of mechanism. Symposium on

Photoprotection. 14th

International Congress on Photobiology. Jeju, Korea, June 10-15,

2004

57. Co-chair. Symposium on Photodermatology. 14th

International Congress on

Photobiology. Jeju, Korea, June 10-15, 2004

58. Photoaging pathophysiology. Department of Dermatology, Kosin University School of

Medicine, Busan, Korea, June 15, 2004

59. Pathophysiology of photoaging. International Symposium on Cosmetic Laser Surgery,

Las Vegas, NV, September 10, 2004

60. Immunopathogenesis of psoriasis. X Jornadas Dermatologicas de Clinica Alemana,

Santiago, Chile, October 1, 2004

61. Retinoids: Pharmacology. X Jornadas Dermatologicas de Clinica Alemana, Santiago,

Chile, October 1, 2004

62. Advances in our understanding of inflammatory acne. X Jornadas Dermatologicas de

Clinica Alemana, Santiago, Chile, October 2, 2004

63. Photoaging pathophysiology. X Jornadas Dermatologicas de Clinica Alemana, Santiago,

Chile, October 2, 2004

64. Topical retinoids and their effect on inflammatory mediators in acne. Dermatology

Update, 20th

Anniversary, Vancouver, Canada, October 16, 2004

65. New findings in inflammatory pathways and scar formation in acne. Symposium on

Recent Progress in Acne Management. 13th

Congress of the European Academy of

Dermatology and Venereology. Florence, Italy, November 18, 2004

66. Evidence for matrix remodeling in inflammatory acne (Invited Plenary Lecture). The

Korean Society for Acne Research. Seoul, Korea, March 5, 2005

67. Advances in our understanding of inflammatory acne. Singapore Acne Symposium.

Singapore, March 31, 2005

68. A new perspective in acne inflammation and its antagonism with retinoids (Invited

Plenary Lecture). Acne Symposium organized by Acne Task Force of the 7th

Asian

Congress of Dermatology. Kuala Lumpur, Malaysia, April 1, 2005

69. Scleroderma with special focus on UVA1 treatment (Invited lecture). Karolinska

Dermatology Symposium, Karolinska University Hospital, Stockholm, Sweden, April 15,

2005

70. A new perspective in acne inflammation and its antagonism by retinoids (Invited lecture).

Asian Scientific Forum at the Society for Investigative Dermatology. St. Louis, MO,

May 6, 2005

Sewon Kang, M.D.

71. More to learn from Methotrexate. Reunión Anual de Dermatólogos latinoamaercanos.

Santiago, Chile, May 13, 2006

72. Acne: What‟s the lack of connection with psoriasis? Reunión Anual de Dermatólogos

latinoamaercanos. Santiago, Chile, May 13, 2006

73. UVA1 for scleroderma. Reunión Anual de Dermatólogos latinoamaercanos. Santiago,

Chile, May 14, 2006

74. Skin aging: Current concept. Reunión Anual de Dermatólogos latinoamaercanos.

Santiago, Chile, May 14, 2006

75. Acne inflammation and matrix degradation. National Skin Center, Singapore, October

12, 2006

76. Dermatologic research: excitement and challenges. National Skin Center, Singapore,

October 12, 2006

77. Ultraviolet A1 phototherapy of scleroderma. National Skin Center, Singapore, October

13, 2006

78. Pathophysiology & treatment of skin aging. Chapter of Dermatologists Lecture,

Singapore College of Physicians, Singapore, October 13, 2006

79. Optimizing acne treatment with topical retinoid: based on pathophysiology and clinical

evidence. The 70th

Annual Meeting of the Tokyo Division of Japanese Dermatological

Association, Tokyo, February 17, 2007

80. Mechanical tension and fibroblast function: lessons learned from cross-linked hyaluronic

acid filler injections into photoaged human skin. Department of Dermatology, Asan

Medical Center, Seoul, Korea, April 11, 2007.

81. Photoaging prevention by a soy extract genistein. Kyung Hee University, College of

Oriental Medicine, Seoul, Korea, April 13, 2007.

82. Retinoids in prevention and therapy of photoaging. Symposium on The Aging Skin, The

16th

Congress of the European Academy of Dermatology and Venereology, Vienna,

Austria, May 18, 2007.

83. New approaches to retinoid therapy. Symposium “Dermatotherapy- The classics”, The

21st World Congress of Dermatology, Buenos Aires, Argentina, October 1, 2007.

84. New perspectives in acne inflammation. Satellite Symposium “Facing the future:

unconventional approaches to acne management”, 21st World Congress of Dermatology,

Buenos Aires, Argentina, October 3, 2007

85. Does enough evidence now exist for using lasers and other procedures to treat acne?

Satellite Symposium “Facing the future: unconventional approaches to acne

management”, 21st World Congress of Dermatology, Buenos Aires, Argentina, October

3, 2007

Sewon Kang, M.D.

86. Inflammatory pathways that lead to scarring. Meeting of Minds “ Inflammatory acne:

can we prevent/reduce scarring?”, 21st World Congress of Dermatology, Buenos Aires,

Argentina, October 5, 2007

87. Skin of color: teaching us to be better clinicians/investigators. The L‟Oreal Institute for

Ethnic Hair & Skin Research: 4th

International Symposium, Miami, FL November 10,

2007.

88. Retinoid signaling in human skin in vivo. Symposium on Advances in Acne – global

impact, pathogenesis, treatment & research. International Investigative Dermatology

2008, Kyoto, Japan, May 14, 2008.

89. Acne and dermal tissue. Sebaceous gland, acne, rosacea and related disorders: Basic and

clinical research, clinical entities and treatment. Rome, Italy, September 14, 2008.

90. Inflammation and scar formation in acne. 8th

Asian Dermatological Congress. Seoul,

Korea, October 1, 2008.

91. Advances in photoaging: an inside-out to outside-in story (Invited Plenary Lecture). 8th

Asian Dermatological Congress. Seoul, Korea, October 2, 2008.

92. Mode of action of retinoids in acne. 8th

Asian Dermatological Congress. Seoul, Korea,

October 2, 2008.

93. What‟s new in the pathophysiology of photoaging. XXVI – RADLA, Mexico City,

Mexico, July 7, 2009.

94. Dermatology residency training in the USA: Johns Hopkins experience. Department of

Dermatology, Seoul Asan Medical Center. Seoul, Korea, November 9, 2009.

95. Mechanism of action of treatment modalities for photoaging. The 5th

Annual Meeting of

the Chinese Dermatologists Association. Suzhou, China. November 11, 2009.

96. Pathophysiology of photoaging. The 5th

Annual Meeting of the Clinical Dermatologist

Association. Suzhou, China, November 13, 2009.

PRESENTATIONS: NATIONAL

1. Etretinate therapy for psoriasis inhibits both serum chemotaxis for and cytolytic activity

by neutrophils. National Clinical Dermatology Conference, Chicago, June, 1983

2. Improvement in glucose tolerance and insulin sensitivity during etretinate therapy for

psoriasis. American Academy of Dermatology Summer Session, San Diego, June, 1985

3. Report on Midwest Student Medical Research Forum XVII to the American Medical

Association - Education Research Foundation Council, National Student Research

Forum, Galveston, April, 1986

Sewon Kang, M.D.

4. Phenotype and antigen presenting cell function of murine dermal cells. National Student

Research Forum, Galveston, April, 1987

5. Multiple primary melanoma: implications in patient management. American Federation

for Clinical Research Joint Subspecialty Meeting, Washington DC, May 1990

6. Retinoids improve granulomatous dermatitis. American Academy of Dermatology,

Atlanta, December, 1990

7. Clinical characterization of psoriatic plaques in vivo using digital microscopy. American

Academy of Dermatology, Atlanta, December, 1990

8. In vivo characterization of pigment patterns in dysplastic nevi using digital

epiluminescence microscopy. American Academy of Dermatology, Atlanta, December,

1990

9. Histologic regression in malignant melanoma: an interobserver concordance study.

American Society of Dermatopathology, Atlanta, November, 1990

10. Melanoma and melanoma precursors - pigment pattern characterization in vivo using

computer-assisted epiluminescence microscopy. American Society of

Dermatopathology, Atlanta, November, 1990

11. Melanoma risk is increased in patients with atypical nevi even with close follow-ups.

Society for Investigative Dermatology, Seattle, May, 1991

12. Digital epiluminescence microscopy (Digital ELM) - a noninvasive tool for improving

the differential diagnosis of pigmented lesions. American Academy of Dermatology,

Dallas, December 1991

13. Identification of the skin phototype - new data on self-reporting versus interview.

Photobiology: science and clinical practice (Course 206). American Academy of

Dermatology, Dallas, December, 1991

14. Digital Epiluminescence Microscopy: Massachusetts General Hospital Experience.

Strategies in the Early Detection and Prevention of Melanoma (Forum 519). American

Academy of Dermatology, Dallas, December, 1991

15. Class II MHC+ cells in the dermis exhibit the phenotypic, ultrastructural and functional

characteristics of dermal Langerhans cells. Society for Investigative Dermatology,

Baltimore, April, 1992

16. Grading protocol for clinical diganosis of pigmented lesions using digital

epiluminescence microscopy. American Society of Dermatopathology, San Francisco,

December 1992

17. Update on digital epiluminescence microscopy. American Academy of Dermatology,

San Francisco, December 1992

Sewon Kang, M.D.

18. Topical retinol induces CRABP-II mRNA expression and epidermal hyperplasia but only

trace erythema in human skin in vivo. Society for Investigative Dermatology,

Washington DC, April 1993

19. Tumor vascularity as a prognostic factor in cutaneous malignant melanoma. Society for

Investigative Dermatology, Washington DC, April 1993

20. Early detection of melanoma by visualizing perturbations of pigment network

morphology using digital epiluminescence microscopy. American Academy of

Dermatology, Washington DC, December 1993

21. Metabolism of retinoids in skin. Retinoid Symposium. American Academy of

Dermatology, Washington D.C., December, 1993

22. Topical retinol increases retinyl ester but not retinoic acid content and enhances

expression of cellular retinol binding protein mRNA and protein in normal human skin in

vivo. Society for Investigative Dermatology, Baltimore MD, April 1994

23. All-trans, 9-cis, 13-cis retinoic acid each induce a Cytochrome P-450 4-retinoic acid

hydroxylase which causes all-trans but not 9-cis or 13-cis retinoic acid to self-

metabolize. Society for Investigative Dermatology, Baltimore MD, April 1994

24. Topical retinol increases retinyl-ester but not retinoic acid content and enhances

expression of CRBP mRNA and protein in normal human skin in-vivo. FASEB Summer

Research Conference on Retinoids, Copper Mountain, Colorado, June 1994

25. The utility of prolonged occlusion in the treatment of psoriasis. Psoriasis Symposium,

Chicago IL, July 1994

26. Topical tretinoin improves systemic steroid-induced striae distensae. American Academy

of Dermatology, New Orleans, February, 1995

27. Liarozole plus retinol application increases human skin retinoic acid levels producing a

typical retinoid response without irritation. Society for Investigative Dermatology,

Chicago IL, May 1995

28. Ultraviolet irradiation rapidly upregulates transcription factors AP-1 and NF-kB and

subsequently induces expression of target genes for matrix-degrading metalloproteinases

in human skin in-vivo. Society for Investigative Dermatology, Chicago IL, May, 1995

29. Metabolism of retinoids in human skin. Focus Session. American Academy of

Dermatology, Washington D.C., February, 1996

30. Retinoid-X-receptor ligand 9-cis retinoic acid synergistically enhances the activation of

vitamin D-responsive 24-hydroxylase gene by 1,25(OH)2D3 in human skin in-vivo.

Keystone Symposia on Molecular and Cellular Biology: Sterioid/Thyroid/Retinoic Acid

Gene Family, Lake Tahoe, CA, March, 1996

31. Activation of the vitamin D-responsive 24-hydroxylase gene by 1,25(OH)2D3 is

synergistically enhanced by retinoid-X receptor ligand 9-cis retinoic acid and by the 24-

Sewon Kang, M.D.

hydroxylase inhibitor ketoconazole in human skin in-vivo. Society for Investigative

Dermatology (for the General Plenary Session), Washington DC, May 1996

32. RXR agonists or 24-hydroxylase inhibitors increase the activity of vitamin D3. FASEB

Summer Research Conference on Retinoids, Copper Mountain, Colorado, June 1996

33. Dermatopharmacology of vitamins A and D. American Academy of Dermatology,

Academy „96, Orlando, July 1996

34. Basic Immunopathogenesis of psoriasis. New England Dermatological Society and

National Psoriasis Foundation Symposium on Psoriasis, Boston, November, 1996

35. Metabolism of retinoids in human skin: Focus session. American Academy of

Dermatology, San Francisco, March 1997

36. Retinoid/steroid nuclear receptors in skin - how do they work. American Academy of

Dermatology, San Francisco, March 1997

37. Tretinoin therapy of striae. The Evolving Role of Retinoids in the Management of

Cutaneous Conditions. Cleveland Clinic Foundation. New York, NY, May 1997

38. Metabolism and molecular action of vitamin D3 and its analogs. University of Chicago,

Chicago, Illinois, July 1997

39. Retinoids-Past, Present, Future. Symposium on current concepts in acne and rosacea.

Academy „97, New York, July 1997

40. Skin pharmacology of vitamins A and D. Academy „97, New York, August 1997

41. Deltanoids. New therapeutic approaches for psoriasis. Academy „97, New York, August

1997

42. Retinoid dermatitis: its molecular basis and clinical implications. Buffalo/Rochester

Dermatology Society, Rochester, New York, October, 1997

43. Vitamin D3 metabolism and action in human skin in-vivo. University of Rochester,

Strong Memorial Hospital, Rochester, New York, October, 1997

44. Retinoid metabolism in human skin. American Academy of Dermatology, Orlando,

March, 1998

45. Immunosuppressive drugs for dermatology. American Academy of Dermatology,

Orlando, March, 1998

46. Molecular basis of retinoid effects on photoaging (Invited lecturer). Twenty-sixth

Annual Meeting of the American Society for Photobiology, Snowbird, Utah, July 1998

47. Management of photoaging. Symposium on Sun Protection & Photodamage: New

Insight. Academy „98, Chicago, July, 1998

Sewon Kang, M.D.

48. Retinoids & deltanoids in skin pharmacology. Academy „98, Chicago, August, 1998

49. Psoriasis as an autoimmune disease: Novel therapeutic approaches. Academy „98,

Chicago, August, 1998

50. Molecular mechanism of tretinoin in photoaging. American Academy of Dermatology,

New Orleans, March, 1999

51. Retinoids: Understanding its mechanism of action. American Academy of Dermatology,

New Orleans, March, 1999

52. Immunosuppressive drugs for dermatology. American Academy of Dermatology, New

Orleans, March, 1999

53. The antioxidant N-acetyl cysteine increases the content of the endogenous antioxidant

glutathione and prevents UV-induction of matrix metalloproteinases in human skin in

vivo. Society for Investigative Dermatology, Chicago, May, 1999

54. Psoriasis- An immunologic disease. Annual Meeting of the Massachusetts Academy of

Dermatology, North Falmouth, October, 1999

55. Therapeutic update in atopic dermatitis. Annual Meeting of the Massachusetts Academy

of Dermatology, North Falmouth, October, 1999

56. Understanding the side-effect of topical retinoids. American Academy of Dermatology,

San Francisco, March, 2000

57. Understanding the cutaneous side effects of topical tretinoin. Symposium on Photoaging

and Intrinsic Aging of the Skin, Academy 2000, Nashville, August, 2000

58. What are barriers to conducting clinical research in dermatology. Annual Meeting of

Professors of Dermatology, Inc., Chicago, September, 2000

59. Ultraviolet A1 phototherapy for scleroderma. National Institute of Health, National

Cancer Institute, Dermatology Branch, Bethesda, February, 2001

60. Photoaging pathophysiology, treatment and prevention. Department of Dermatology,

University of Pittsburgh, Pittsburgh, February, 2001

61. The role of metalloproteinases in acne. A Symposium on Advances in Acne Research,

Society for Investigative Dermatology, Washington, DC, May, 2001

62. Antioxidants for photoaging prevention. Photoprotection Symposium. 29th

Annual

Meeting of the American Society for Photobiology, Chicago, July, 2001

63. The physiologic and pharmacologic action of retinoid receptors. Visiting Professor

Program, Center for Drug Evaluation and Research, U.S. Food and Drug Administration,

Rockville, MD, July 19, 2001

Sewon Kang, M.D.

64. Latest finding for retinoids in photodamage. Symposium on Innovations in Improving

Facial Appearance. Academy 2001, Annaheim, CA, July, 2001

65. Elucidating the pathophysiologic mechanism of photoaging in vivo. The 10th

Annual R.

William Gange Lecturer. The Wellman Laboratories of Photomedicine, Massachusetts

General Hospital, Boston, MA, November 27, 2001

66. Psoriasis. Poster discussion session moderator. American Academy of Dermatology,

New Orleans, LA, February, 2002.

67. Pathophysiology and the treatment of photodamage. Valley of the Sun Conference on

Clinical Dermatology, Scottsdale, AZ, April 28, 2002.

68. Retinol, retinoic acid, retinyl esters... what‟s the difference? Valley of the Sun

Conference on Clinical Dermatology, Scottsdale, AZ, April 28, 2002.

69. Matrix alterations in skin aging and retinoid antagonism. 2nd

Annual Aging Skin

Conference, University of Minnesota, Minneapolis, MN, May 3, 2002.

70. Symposium chair – Photodamage: pathogenesis, manifestations, prevention, and

treatment. Academy 2002, New York, NY, July 31, 2002.

71. Recent advances in photoaging. Academy 2002, New York, NY, August 3, 2002.

72. Retinol: a retinoid. 1st Annual meeting of the American Society of Cosmetic

Dermatology & Aesthetic Surgery, Las Vegas, NV, December 8, 2002.

73. Pharmacologic dissection of psoriasis. Winter Skin Seminar, Snowmass, CO, February

3, 2003

74. New concept in acne scarring. Winter Skin Seminar, Snowmass, CO, February 4, 2003

75. Histologic evaluation of photoaged skin. Symposium on photoaging. Hawaii

Dermatology Seminar, Maui, February 16, 2003

76. Clinical Research in Dermatology. National Institute of Arthritis Musculoskeletal and

Skin Diseases, National Institutes of Health, Bethesda, MD, March 3, 2003

77. A mechanism of matrix destruction in inflammatory acne. Skin Disease Research Center,

Department of Dermatology, Case Western University School of Medicine, Cleveland,

OH, March 13, 2003

78. New topical immunomodulators for atopic dermatitis. American Academy of

Dermatology, San Francisco, CA, March 22, 2003

79. Photoaging. Valley of the Sun Conference on Clinical Dermatology, Scottsdale, AZ,

May 18, 2003

80. Antioxidants and photoaging. Photoaging & Photoprotection Symposium. The 31st

Annual Meeting of the American Society for Photobiology, Baltimore, MD, July 7, 2003

Sewon Kang, M.D.

81. Current perspective on acne inflammation and scarring. Symposium on Improving the

treatment of inflammatory acne. Academy ‟03, Chicago, IL, July 25, 2003

82. Scleroderma & phototherapy. Academy ‟03, Chicago, IL, July 28, 2003

83. New perspective on the pathogenesis of acne: focus on understanding inflammatory

pathways. American Academy of Dermatology, Washington DC, February 7, 2004

84. Scleroderma & phototherapy. American Academy of Dermatology, Washington DC,

February 10, 2004

85. Immunopharmacology of psoriasis. Movitz Visiting Professor in Psoriasis, University of

Utah, Department of Dermatology, Salt Lake City, Utah, February 27, 2004

86. Learning dermatology/medical science from psoriasis patients. Movitz Visiting Professor

in Psoriasis, University of Utah, Department of Dermatology, Salt Lake City, Utah,

February, 27, 2004

87. Treatment-Directed Pathophysiology. DF: Clinical Symposia Advances in Dermatology,

Amelia Island, Florida, March 18, 2004

88. Retinoids. DF: Clinical Symposia Advances in Dermatology, Amelia Island, Florida,

March 20, 2004

89. Anti-Inflammatory Effects of Retinoids. DF: Clinical Symposia Advances in

Dermatology, Amelia Island, Florida, March 20, 2004

90. Co-chair. Symposium on Photoprotection and Photoaging. 32nd

Annual Meeting of the

American Society for Photobiology. Seattle, Washington, July 12, 2004

91. Update on antioxidants in photoaging. 32nd

Annual Meeting of the American Society for

Photobiology. Seattle, Washington, July 12, 2004

92. Photoaging and skin of color. Academy ‟04, New York, New York, July 31, 2004

93. Actinic keratoses and photodamage: Clinical experience with topical retinoids.

Symposium in Expanding the Therapeutic Horizon for Topical Retinoids. Academy ‟04,

New York, New York, July 31, 2004

94. UVA1 phototherapy of scleroderma. Department of Dermatology, Oregon Health &

Science University, Portland, Oregon, August 13, 2004

95. Photoaging pathophysiology. Oregon Dermatology Society Annual Meeting, Sunriver,

Oregon, August 14, 2004

96. New concept in acne inflammation. Oregon Dermatology Society Annual Meeting,

Sunriver, Oregon, August 15, 2004

Sewon Kang, M.D.

97. Molecular aspects of photodamage and retinoid therapy. Avon at Penn meeting,

Philadelphia, Pennsylvania, October 15, 2004

98. UVA1 phototherapy of scleroderma. Department of Dermatology, UCLA, Los Angeles,

December 21, 2004

99. Photoaging: pathogenesis, treatment and prevention. Division of Dermatology,

University of California San Diego, Feb 10, 2005

100. Scleroderma & phototherapy. American Academy of Dermatology, New Orleans, LA,

February 19, 2005

101. Update on antioxidants in photoaging. American Academy of Dermatology, New

Orleans, LA, February 20, 2005

102. Induction of matrix metalloproteinases and inhibition of procollagen synthesis in human

skin in vivo by ultraviolet A1 irradiation is profoundly diminished by skin pigmentation.

American Academy of Dermatology, New Orleans, LA, February 20, 2005

103. Introductory lecture to minisymposium on Clinical Research and Therapeutics. Society

for Investigative Dermatology, St. Louis, MO, May 5, 2005

104. How a soy extract genistein affects UV inflammation. Symposium on advancing the

science of naturals, Academy ‟05, Chicago, Illinois, July 22, 2005

105. Antioxidants and prevention of photoaging. Seminar in advances in photoprotection and

photoaging, Academy ‟05, Chicago, Illinois, July 23, 2005

106. Ultraviolet-A1 phototherapy of scleroderma. 125th

Annual Meeting of the American

Dermatological Association, Greensboro, GA, September 15, 2005.

107. Pathophysiology of photoaging. Department of Dermatology, SUNY Downstate Medical

Center, Brooklyn, NY, September 21, 2005.

108. UVA1 phototherapy of scleroderma. Department of Dermatology, SUNY Downstate

Medical Center, Brooklyn, NY, September 21, 2005.

109. Basics of skin photodamage and aging. SID Basics of Skin: Pharmaceutics and

Pharmacology course. San Antonio, TX, October 7, 2005.

110. Aging workshop. SID Basics of Skin: Pharmaceutics and Pharmacology course. San

Antonio, TX, October 7, 2005.

111. UVA1 and scleroderma. Brooke Army Medical Center, San Antonio, TX, February 2,

2006.

112. Acne inflammation. Brooke Army Medical Center, San Antonio, TX, February 2, 2006.

113. Rationale for the use of antioxidants in photoaging prevention. Advanced Technology

Conference America, Miami, FL, February 6, 2006.

Sewon Kang, M.D.

114. Scleroderma and phototherapy. American Academy of Dermatology, San Francisco, CA,

March 4, 2006.

115. Evidence for matrix degradation in inflammatory acne. Department of Dermatology,

Stanford School of Medicine, Palo Alto, CA, March 20, 2006.

116. Mechanisms of action of drugs in acne. Valley of the Sun Conference, Phoenix, AZ,

April 1, 2006.

117. Inflammatory acne and matrix remodeling. Symposium on Advances in Acne Research,

Society for Investigative Dermatology, Philadelphia, PA, May 3, 2006.

118. The role of retinoids in preventing and treating skin aging changes. The 35th

Annual

Meeting of the American Aging Association, Boston, MA, June 4, 2006.

119. Advances in the pathophysiology of photoaging. Academy ‟06, San Diego, CA, July 27,

2006.

120. Effects of UV in pigmented human skin. Academy ‟06, San Diego, CA, July 27, 2006.

121. Basics of skin and aging. SID Basics of Skin: Pharmaceutics and Pharmacology course.

San Diego, CA, October 20, 2006.

122. Aging workshop. SID Basics of Skin: Pharmaceutics and Pharmacology course. San

Diego, CA, October 20, 2006.

123. Inflammation and matrix remodeling in acne. Skin Disease Research Center, University

of Alabama, Birmingham, AL, December 6, 2006.

124. Scleroderma and phototherapy. American Academy of Dermatology, Washington DC,

February 5, 2007.

125. Photoaging – how does the sun make us look old? And what are the topical strategies for

treatment? American Academy of Dermatology, Washington DC, February 5, 2007.

126. Harnessing UV light to improve skin fibrosis. Khosrow Momtaz, MD Memorial Lecture,

Harvard Medical School, Department of Dermatology, Massachusetts General Hospital,

Boston, MA, March 1, 2007.

127. Skin aging. SID Basics of Skin: Pharmaceutics and Pharmacology course. Miami, FL

December 7, 2007

128. Retinoids & Antioxidants. SID Basics of Skin: Pharmaceutics and Pharmacology course.

Miami, FL December 7, 2007

129. Computer- assisted alignment and tracking of acne lesions. The 3rd

Annual Meeting of

the American Acne & Rosacea Society. San Antonio, TX, February 1, 2008.

Sewon Kang, M.D.

130. Photaging- how does the sun make us look old? And what are the topical strategies for

treatment? American Academy of Dermatology, San Antonio, TX, February 1, 2008.

131. Update on acne scarring. American Academy of Dermatology, San Antonio, TX,

February 2, 2008.

132. Understanding topical retinoids‟ effects & side-effects. American Academy of

Dermatology, February 5, 2008.

133. Evidence-based therapy of scleroderma with UVA-1. Department of Dermatology,

University of Texas Southwestern Medical Center, Dallas, TX, June 19, 2008.

134. The Pharmacology of retinoids in human skin. Symposium on the changing the face of

acne therapy, Academy ‟08, Chicago, IL, August 1, 2008.

135. Natural skin aging and topical retinol: pathogenesis & potential therapy. Duhring

Lectureship, Department of Dermatology, University of Pennsylvania School of

Medicine. Philadelphia, PA, December 4, 2008.

136. Update on photoaging. 86th

Atlantic Dermatological Conference. Baltimore, MD, April

3, 2009.

137. Topical 5-FU Improves Photoaging Society for Investigative Dermatology, Montreal,

Canada. May 7, 2009.

138. How sun makes you look old. The 26th

Annual Convention and Scientific Meeting of the

Seoul National University College of Medicine Alumni Association of America,

Dearborn, MI, July 6, 2009.

139. Photoaging: topical drugs (retinoids). 129th

Annual Meeting of the American

Dermatological Association, Park City, Utah, August 20, 2009.

140. Photoaging. Henry Menn Memorial lecture, The 36th

annual Meeting of the Masters

Dermatologic Association, Pinehurst, North Carolina. October 20, 2009.

141. Retinoid pharmacology in human skin. Department of Dermatology, University of

Cincinnati, Cincinnati, Ohio. December 2, 2009.

142. Photoaging pathophysiology. Cincinnati Dermatological Society, Cincinnati, Ohio.

December 2, 2009.

143. UVA-1 phototherapy of scleroderma. Cincinnati Dermatological Society, Cincinnati,

Ohio. December 3, 2009.

PRESENTATIONS: LOCAL AND REGIONAL

1. Etretinate therapy for psoriasis inhibits both serum chemotaxis and cytolytic activity by

neutrophils. University of Michigan Student Medical Research Forum, Ann Arbor,

October, 1983

Sewon Kang, M.D.

2. Immunologic effects of etretinate therapy for psoriasis. XVth Midwest Student Medical

Research Forum, Madison, March, 1984

3. Etretinate therapy enhances glucose metabolism. University of Michigan Student

Medical Research Forum, Ann Arbor, October, 1984

4. Glucose metabolism during etretinate administration. XVth Midwest Student Medical

Research Forum, Dayton, March, 1985

5. Retinoids: Can a hyperlipidemic agent treat diabetes? Michigan Diabetes and Research

and Training Center. Workshop on Complications of Diabetes, Ann Arbor, June, 1985

6. Phenotypic and functional study on dermal antigen presenting cells in mouse. Midwest

Student Research Forum XVIII, Louisville, February, 1987

7. Our maturing skin. Lurie Terrace Senior Citizens Housing Inc., Ann Arbor, January,

1993

8. Sun-induced skin problems. Family Practice Spring Review, University of Michigan

Medical Center, Ann Arbor, March, 1993

9. New perspectives in antifungal therapy. The 96th Annual Convention of the Indiana

Association of Osteopathic Physicians and Surgeons, Indianapolis, May 1993

10. Selected common dermatoses - diagnosis and treatment. University of Michigan Internal

Medicine Noon Conference, Ann Arbor, April 1994

11. Metabolism of retinoids in human skin. The Michigan Dermatological Society, Ann

Arbor, March 1995

12. Cutaneous manifestations of HIV infection. Invited Speaker at the Twelfth Annual

Meeting of the Korean-American Medical Association of Michigan, Bay City, Michigan,

May 1995

13. A view from clinical pharmacology unit. Psoriasis symposium at the Michigan

Dermatological Society, Ann Arbor, March 1996

14. The importance of aging skin research. Lurie Terrace Senior Citizens Housing Inc., Ann

Arbor, September, 1996

15. Clinical management of acne vulgaris - rationale for topical retinoids. Broward County

Dermatology Society Meeting, Florida, February, 1997

16. Retinoic acid therapy of skin diseases. Michigan Dermatological Society Meeting, Ann

Arbor, February, 1998

17. Ultraviolet A1 for the treatment of scleroderma: bad news from photoaging turned good.

University of Michigan, Rackham Arthritis Research Unit Seminar Series, Ann Arbor,

February, 2000

Sewon Kang, M.D.

18. Ultraviolet A1 phototherapy for scleroderma. Michigan Dermatological Society, Ann

Arbor, February, 2000

19. Treating scleroderma with UVA1. Dermatology Sesquicentennial Grand Rounds, Ann

Arbor, October, 2000

20. Skin photoaging– elucidating its pathophysiology. Korean-American Medical

Association of Michigan Scientific Seminar, Mt. Pleasant, Michigan, May, 2001

21. Immunopharmacology of psoriasis. University of Michigan Medical Center, General

Clinical Research Center Seminar Series, Ann Arbor, June, 2001

22. New Views on Acne. Michigan Dermatological Society, Ann Arbor, March, 2002

23. Ultraviolet A1 phototherapy for sclerodermoid graft versus host disease. Seminar in

Bone Marrow Transplant Service, University of Michigan Health System, Ann Arbor,

March, 2002

24. Photoaging science update for the practitioner. The 11th

Annual Dermatology Visiting

Professor Program. NEOUCOM, Cleveland, Ohio, November, 2002

25. UVA1 Phototherapy of scleroderma: an update. Seminar at the Rackham Arthritis

Research Unit, Division of Rheumatology, University of Michigan Health System, Ann

Arbor, January 15, 2003

26. Advances in acne therapy. The University of Michigan Student Health Service

Continuing Medical Education Program. Ann Arbor, February 20, 2003

27. Photoaging pathophysiology. Department of Dermatology, Wayne State University

School of Medicine. Detroit, March 5, 2003

28. Immunopathophysiology of psoriasis. Department of Dermatology, Henry Ford Health

System, West Bloomfield, June 7, 2003

29. Update on acne and rosacea. Multidisciplinary Conference, Flower Hospital, Sylvania,

Ohio, February 24, 2004

30. Cutaneous manifestation of internal diseases. Grand Rounds Department of Family

Medicine, University of Michigan, February 25, 2004

31. Clinical Pharmacology Unit. Dermatology Dialouges, Department of Dermatology,

University of Michigan, April 13, 2004

32. Softening the Skin of Scleroderma with Phototherapy. Scleroderma Foundation,

Michigan Chapter, Patient Education Seminar, University of Michigan, October 10, 2004

33. Photoaging: pathogenesis, treatment and prevention. Michigan Center for Oral Health

Research, The 1st Research Seminar. University of Michigan, School of Dentistry,

January 19, 2005

Sewon Kang, M.D.

34. UVA1 Update. Michigan Dermatological Society, Ann Arbor, April 6, 2005

35. How the summer research program shaped my career path. Student Biomedical Fall

Research Forum, Ann Arbor, November 2, 2006

36. Retinol treatment of naturally aged skin. Michigan Dermatological Society, Ann Arbor ,

April 30, 2008

37. UVA-1 photography of scleroderma. Maryland Dermatological Society, Johns Hopkins

Medicine, Baltimore, Maryland, November 6, 2008.

38. Skin deep. A Women‟s Journey, Johns Hopkins Medicine, Palm Beach, Florida, January

22, 2009.

39. Dermatology for the internist. 12th

Annual Johns Hopkins Internal Medicine Board

Review. Baltimore, MD, July 15, 2009.

40. New insights into acne inflammation. Johns Hopkins Asthma & Allergy Center,

Divisional Research Conference. Baltimore, MD, October 28, 2009.

curriculum vitae sewon kang, m.d. current ...december, 2009 curriculum vitae sewon kang, m.d....

Documents